

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/46170 A2

(51) International Patent Classification⁷: C07D 239/00

(74) Agents: INSOGNA, Anthony, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(21) International Application Number: PCT/US01/46402

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 5 December 2001 (05.12.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/251,904 6 December 2000 (06.12.2000) US

(71) Applicant: SIGNAL PHARMACEUTICALS, INC.
[US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US).

(72) Inventors: KOIS, Adam; 11363 Redbud Court, San Diego, CA 92127 (US). MACFARLANE, Karen, J.; 11435 Belshire Lane, San Diego, CA 92126 (US). SATOH, Yoshitaka; 11460 Larmier Circle, San Diego, CA 92131 (US). BHAGWAT, Shripad, S.; 5015 Ashley Falls Court, San Diego, CA 92130 (US). PARNES, Jason, S.; 12511 El Camino Real #C, San Diego, CA 92130 (US). PALANKI, Moorthy, S., S.; 602 Crest Drive, Encinitas, CA 92024 (US). ERDMAN, Paul, E.; 8225 Jade Coast #93, San Diego, CA 92126 (US).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2 (54) Title: ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO

WO 02/46170



(57) Abstract: Compounds having activity as inhibitors of the JNK pathway are disclosed. The compounds of this invention are anilinopyrimidine derivatives having the following structure: (I) wherein R₁ through R₆ are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO

5 This application claims the benefit of U.S. Provisional Application No. 60/251,904, filed December 6, 2000, incorporated by reference herein in its entirety..

1. FIELD OF THE INVENTION

10 This invention is generally directed to anilinopyrimidine derivatives which have utility as Jun N-terminal kinase (JNK) pathway inhibitors and related compositions and methods.

2. BACKGROUND OF THE INVENTION

The Jun N-terminal kinase (JNK) pathway is activated by exposure of cells to environment stress or by treatment of cells with pro-inflammatory cytokines. Targets of the JNK pathway include the transcription factors c-jun and ATF-2 (Whitmarsh A.J., and Davis R.J. . *J. Mol. Med.* 74:589-607, 1996). These transcription factors are members of the basic leucine zipper (bZIP) group that bind as homo- and hetero-dimeric complexes to AP-1 and AP-1-like sites in the promoters of many genes (Karin M., Liu Z.G. and Zandi E. *Curr Opin Cell Biol* 9:240-246, 1997). JNK binds to the N-terminal region of c-jun and ATF-2 and phosphorylates two sites within the activation domain of each transcription factor (Hibi M., Lin A., Smeal T., Minden A., Karin M. *Genes Dev.* 7:2135-2148, 1993; Mohit A.A., Martin M.H., and Miller C.A. *Neuron* 14:67-75, 1995). Three JNK enzymes have been identified as products of distinct genes (Hibi et al, *supra*; Mohit et al., *supra*). Ten different isoforms of JNK have been identified. These represent alternatively spliced forms of three different genes: JNK1, JNK2 and JNK3. JNK1 and 2 are ubiquitously expressed in human tissues, whereas JNK3 is selectively expressed in the brain, heart and testis (Dong, C., Yang, D., Wysk, M., Whitmarsh, A., Davis, R., Flavell, R. *Science* 270:1-4, 1998). Gene transcripts are alternatively spliced to produce four-JNK1 isoforms, four-JNK2 isoforms and two-JNK3 isoforms. JNK1 and 2 are expressed widely in mammalian tissues, whereas JNK3 is expressed almost exclusively in the brain. Selectivity of JNK signaling is achieved via specific interactions of JNK pathway components and by use of scaffold proteins that selectively bind multiple components of the signaling cascade. JIP-1 (JNK-interacting protein-1) selectively binds the MAPK module, MLK → JNKK2 → JNK.12,13. It has no binding affinity for a variety of other MAPK cascade enzymes. Different scaffold proteins are likely to exist for other MAPK signaling cascades to preserve substrate specificity.

JNKs are activated by dual phosphorylation on Thr-183 and Tyr-185.

JNKK1 (also known as MKK-4) and JNKK2 (MKK-7), two MAPKK level enzymes, can mediate JNK activation in cells (Lin A., Minden A., Martinetto H., Claret F.-Z., Lange-Carter C., Mercurio F., Johnson G.L., and Karin M. *Science* 268:286-289, 1995; Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., and Davis R.J. *Proc. Nat. Acad. Sci. USA* 94:7337-7342, 1997). JNKK2 specifically phosphorylates JNK, whereas JNKK1 can also phosphorylate and activate p38. Both JNKK1 and JNKK2 are widely expressed in mammalian tissues. JNKK1 and JNKK2 are activated by the MAPKKK enzymes, MEKK-1, MEKK-2, MEKK-3 and MLK-3 (Lange-Carter C.A., Pleiman C.M., Gardner A.M., Blumer K.J., and Johnson G.L. *Science* 260:315-319, 1993; Yan M., Dai J.C., Deak J.C., Kyriakis J.M., Zon L.I., Woodgett J.R., and Templeton D.J. *Nature* 372:798-781, 1994; Deacon, K. and Blank, J., *J. Biol. Chem.* 274:16604-16610, 1999; Teramoto, H., Coso, O., Miyata, H., Igishi, T., Miki, T. and Gutkind, S., *J. Biol. Chem.* 271:27225-27228, 1996). Both MEKK-1 and MEKK-2 are widely expressed in mammalian tissues.

Activation of the JNK pathway has been documented in a number of disease settings, providing the rationale for targeting this pathway for drug discovery. In addition, molecular genetic approaches have validated the pathogenic role of this pathway in several diseases. For example, autoimmune and inflammatory diseases arise from the over-activation of the immune system. Activated immune cells express many genes encoding inflammatory molecules, including cytokines, growth factors, cell surface receptors, cell adhesion molecules and degradative enzymes. Many of these genes are regulated by the JNK pathway, through activation of the transcription factors AP-1 and ATF-2, including TNF α , IL-2, E-selectin and matrix metalloproteinases such as collagenase-1 (Manning A.M. and Mercurio F. *Exp. Opin. Invest. Drugs* 6: 555-567, 1997). Monocytes, tissue macrophages and tissue mast cells are key sources of TNF α production. The JNK pathway regulates TNF α production in bacterial lipopolysaccharide-stimulated macrophages, and in mast cells stimulated through the Fc ϵ RII receptor (Swantek J.L., Cobb M.H., Geppert T.D. *Mol. Cell. Biol.* 17:6274-6282, 1997; Ishizuka, T., Tereda N., Gerwins, P., Hamelmann E., Oshiba A., Fanger G.R., Johnson G.L., and Gelfland E.W. *Proc. Nat. Acad. Sci. USA* 94:6358-6363, 1997). Inhibition of JNK activation effectively modulates TNF α secretion from these cells. The JNK pathway therefore regulates production of this key pro-inflammatory cytokine. Matrix metalloproteinases (MMPs) promote cartilage and bone erosion in rheumatoid arthritis, and generalized tissue destruction in other autoimmune diseases. Inducible expression of MMPs, including MMP-3 and MMP-9, type II and IV collagenases, are regulated via activation of the JNK pathway and AP-1 (Gum, R., Wang, H., Lengyel, E.,

Jurez, J., and Boyd, D. *Oncogene* 14:1481-1493, 1997). In human rheumatoid synoviocytes activated with TNF α , IL-1, or Fas ligand the JNK pathway is activated (Han Z., Boyle D.L., Aupperle K.R., Bennett B., Manning A.M., Firestein G.S. *J. Pharm. Exp. Therap.* 291:1-7, 1999; Okamoto K., Fujisawa K., Hasunuma T., Kobata T., Sumida T., and Nishioka K. *Arth & Rheum* 40: 919-92615, 1997). Inhibition of JNK activation results in decreased AP-1 activation and collagenase-1 expression (Han et al., *supra*). The JNK pathway therefore regulates MMP expression in cells involved in rheumatoid arthritis.

Inappropriate activation of T lymphocytes initiates and perpetuates many autoimmune diseases, including asthma, inflammatory bowel disease and multiple sclerosis.

The JNK pathway is activated in T cells by antigen stimulation and CD28 receptor co-stimulation and regulates production of the growth factor IL-2 and cellular proliferation (Su B., Jacinto E., Hibi M., Kallunki T., Karin M., Ben-Neriah Y. *Cell* 77:727-736, 1994; Fans M., Kokot N., Lee L., and Nel A.E. *J. Biol. Chem.* 271:27366-27373, 1996). Peripheral T cells from mice genetically deficient in JNKK1 show decreased proliferation and IL-2 production after CD28 co-stimulation and PMA / Ca2+ ionophore activation, providing important validation for the role of the JNK pathway in these cells (Nishina H., Bachmann M., Oliveria-dos-Santos A.J., et al. *J. Exp. Med.* 186:941-953, 1997). It is known that T cells activated by antigen receptor stimulation in the absence of accessory cell-derived co-stimulatory signals lose the capacity to synthesize IL-2, a state called clonal anergy. This is an important process by which auto-reactive T cell populations are eliminated from the peripheral circulation. Of note, anergic T cells fail to activate the JNK pathway in response to CD3- and CD28-receptor co-stimulation, even though expression of the JNK enzymes is unchanged (Li W., Whaley C.D., Mondino A., and Mueller D.L. *Science* 271: 1272-1276, 1996). Recently, the examination of JNK-deficient mice revealed that the JNK pathway plays a key role in T cell activation and differentiation to T helper 1 and 2 cell types. JNK1 or JNK2 knockout mice develop normally and are phenotypically unremarkable. Activated naive CD4+ T cells from these mice fail to produce IL-2 and do not proliferate well (Sabapathy, K., Hu, Y., Kallunki, T., Schreiber, M., David, J-P., Jochum, W., Wagner, E., Karin, M. *Curr Biol* 9:116-125, 1999). It is possible to induce T cell differentiation in T cells from these mice, generating Th1 cells (producer of IFN- γ and TNF β) and Th2 effector cells (producers of IL-4, IL-5, IL-6, IL-10 and IL-13) [22,23]. Deletion of either JNK1 or JNK2 in mice resulted in a selective defect in the ability of Th1 effector cells to express IFNg. This suggests that JNK1 and JNK2 do not have redundant functions in T cells and that they play different roles in the control of cell growth, differentiation and death. The JNK pathway therefore, is an important point for regulation of T cell responses to antigen.

Cardiovascular disease (CVD) accounts for nearly one quarter of total annual deaths worldwide. Vascular disorders such as atherosclerosis and restenosis result from dysregulated growth of the vessel wall, restricting blood flow to vital organs. The JNK pathway is activated by atherogenic stimuli and regulates local cytokine and growth factor production in vascular cells (Yang, DD, Conze, D, Whitmarsh, AJ, et al, *Immunity*, 9:575, 1998). In addition, alterations in blood flow, hemodynamic forces and blood volume lead to JNK activation in vascular endothelium, leading to AP-1 activation and pro-atherosclerotic gene expression (Aspenstrom P., Lindberg U., and Hall A. *Curr. Biol.* 6:70-77, 1996).

Ischemia and ischemia coupled with reperfusion in the heart, kidney or brain results in cell death and scar formation, which can ultimately lead to congestive heart failure, renal failure or cerebral dysfunction. In organ transplantation, reperfusion of previously ischemic donor organs results in acute leukocyte-mediated tissue injury and delay of graft function. The JNK pathway is activated by ischemia and reperfusion (Li Y., Shyy J., Li S., Lee J., Su B., Karin M., Chien S *Mol. Cell. Biol.* 16:5947-5954, 1996), leading to the activation of JNK-responsive genes and leukocyte-mediated tissue damage. In a number of different settings JNK activation can be either pro- or anti-apoptotic. JNK activation is correlated with enhanced apoptosis in cardiac tissues following ischemia and reperfusion (Pombo CM, Bonventre JV, Avruch J, Woodgett JR, Kyriakis J.M, Force T. *J. Biol. Chem.* 26 :26546-26551, 1994).

Cancer is characterized by uncontrolled growth, proliferation and migration of cells. Cancer is the second leading cause of death with 500,000 deaths and an estimated 1.3 million new cases in the United States in 1996. The role of signal transduction pathways contributing to cell transformation and cancer is a generally accepted concept. The JNK pathway leading to AP-1 appears to play a critical role in cancer. Expression of c-jun is altered in early lung cancer and may mediate growth factor signaling in non-small cell lung cancer (Yin T., Sandhu G., Wolfgang C.D., Burrier A., Webb R.L., Rigel D.F. Hai T., and Whelan J. *J. Biol. Chem.* 272:19943-19950, 1997). Indeed, over-expression of c-jun in cells results in transformation, and blocking c-jun activity inhibits MCF-7 colony formation (Szabo E., Riffe M., Steinberg S.M., Birrer M.J., Linnoila R.I. *Cancer Res.* 56:305-315, 1996). DNA-damaging agents, ionizing radiation and tumor necrosis factor activate the pathway. In addition to regulating c-jun production and activity, JNK activation can regulate phosphorylation of p53, and thus can modulate cell cycle progression (Chen T.K., Smith L.M., Gebhardt D.K., Birrer M.J., Brown P.H. *Mol. Carcinogenesis* 15:215-226, 1996). The oncogene BCR-Ab1, associated with t(9;22) Philadelphia chromosome translocation of chronic myelogenous leukemia, activates JNK and leads to transformation of hematopoietic

cells (Milne D.M., Campbell L.E., Campbell D.G., Meek D W. *J. Biol. Chem.* 270:5511-5518, 1995). Selective inhibition of JNK activation by naturally occurring JNK inhibitory protein, called JIP-1, blocks cellular transformation caused by BCR-Ab1 expression (Raitano A.B., Halpern J.R., Hambuch T.M., Sawyers C.L. *Proc. Nat. Acad. Sci USA* 92:11746-11750, 1995). Thus, JNK inhibitors may block transformation and tumor cell growth.

International Publication No. WO 98/18782 to Celltech Therapeutics Limited discloses 4-pyridyl pyrimidine compounds which are allegedly useful in the prophylaxis and treatment of immune diseases, allergic diseases involving mast cells or eosinophils, and diseases involving inappropriate platelet activation.


Accordingly, there is a need in the art for inhibitors of the JNK pathway. In addition, there is a need for pharmaceutical compositions comprising one or more inhibitors, as well as to methods for treating conditions in animals which are responsive to such inhibitors. The present invention fulfills these needs, and provides further related advantages.

Citation or identification of any reference in Section 2 of this application shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION

In brief, the present invention is directed to compounds having activity as inhibitors of the JNK pathway, and to compositions and methods related thereto.

The compounds of the present invention are "anilinopyrimidine derivatives" having the following structure (I):



wherein R₁ through R₆ are as defined below, and including isomers, prodrugs and pharmaceutically acceptable salts thereof.

In general, the present invention is directed to methods for treating or preventing a condition responsive to inhibition of the JNK pathway, comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

35

The present invention is also directed to methods for treating or preventing an inflammatory or autoimmune condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

5 The present invention is also directed to methods for treating or preventing a cardiovascular, metabolic or ischemic condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

The present invention is also directed to methods for treating or preventing an infectious disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

10 The present invention is also directed to methods for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.


15 The present invention is also directed to methods for treating or preventing stroke, epilepsy, Alzheimer's disease, or Parkinson's disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

20 These and other aspects of this invention will be evident upon reference to the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention. Certain patent and other documents are cited herein to more specifically set forth various aspects of this invention. Each of these documents are hereby incorporated by reference in their entirety.

4. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to anilinopyrimidine derivatives having activity as inhibitors of the JNK pathway, and to compositions and methods related thereto.

25 The anilinopyrimidine derivatives have the following structure (I):



30

including isomers, prodrugs and pharmaceutically acceptable salts thereof,

wherein:

35 R_1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R_7 ;

R₂ is hydrogen;

R₃ is hydrogen or lower alkyl;

R₄ represents one to four optional substituents, wherein each substituent is
the same or different and independently selected from halogen,
5 hydroxy, lower alkyl and lower alkoxy;

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉,
-(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀,
-(CH₂)_aC(=O)NR₉(CH₂)_bC(=O)R₁₀, -(CH₂)_aNR₉C(=O)R₁₀,
10 (CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉R₁₀, -(CH₂)_aOR₉, -(CH₂)_aSO_cR₉
or -(CH₂)_aSO₂NR₉R₁₀;

or R₅ and R₆ taken together with the nitrogen atom to which they are attached
to form a heterocycle or substituted heterocycle;

R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro,
carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl,
15 sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted
aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl,
substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉,
-C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉,
-NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉,
20 -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence
independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl,
aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle,
heterocyclealkyl or substituted heterocyclealkyl;

25 or R₈ and R₉ taken together with the atom or atoms to which they are
attached to form a heterocycle or substituted heterocycle;

a and b are the same or different and at each occurrence independently
selected from 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.

30 In one embodiment of the invention, in the anilinopyrimidine derivatives of
structure (I), R₁ is a substituted or unsubstituted aryl or heteroaryl with the proviso that the
heteroaryl is not pyridyl. When R₁ is substituted, it is substituted with one or more
substituents defined below. Preferably, when substituted, R₁ is substituted with a halogen,
sulfone or sulfonamide.

35

In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.

5

In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not imidazo[1,2-a]pyrid-3-yl or pyrazolo[2,3-a]pyrid-3-yl. When R₁ is substituted, it is substituted with one or more substituents defined below. Preferably, when 10 substituted, R₁ is substituted with a halogen, sulfone or sulfonamide.

10

In another embodiment of the invention, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl, preferably phenyl. When R₁ is a substituted aryl, the substituents are defined below. Preferably, when substituted, R₁ is substituted with a halogen, sulfone or sulfonamide.

15

In another embodiment of the invention, in anilinopyrimidine derivatives of structure (I), R₅ and R₆, taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen-containing non-aromatic heterocycle, preferably piperazinyl, piperidinyl or morpholinyl.


20

When R₅ and R₆, taken together with the nitrogen atom to which they are attached form substituted piperazinyl, piperadinyl or morpholinyl, the piperazinyl, piperadinyl or morpholinyl is substituted with one or more substituents defined below. Preferably, when substituted, the substituent is alkyl, amino, alkylamino, alkylether, acyl, pyrrolidinyl or piperidinyl.

25

In one embodiment of the invention, in the anilinopyrimidine derivatives of structure (I), R₃ is hydrogen and R₄ is not present, and the compounds of this invention have the following structure (II):


30



35


In a more specific embodiment of the invention, in the anilinopyrimidine derivatives of structure (II), R₁ is phenyl optionally substituted with R₇, and having the following structure (III):

5



In still a further embodiment of the invention, in the anilinopyrimidine derivatives of structure (III), R₇ is at the para position relative to the pyrimidine, as represented by the following structure (IV):

15



20

As used herein, the terms used above having following meaning:

“Alkyl” means a straight chain or branched, saturated or unsaturated alkyl, cyclic or non-cyclic hydrocarbon having from 1 to 10 carbon atoms, while “lower alkyl” has the same meaning but only has from 1 to 6 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms (also referred to as an “alkenyl” or “alkynyl”, respectively). Representative straight chain and branched alkenyls include ethylenyl, propylenyl, 1-but enyl, 2-but enyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-but enyl, 2-methyl-2-but enyl, 2,3-dimethyl-2-but enyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, and the like. Representative saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic alkyls include cyclopentenyl and cyclohexenyl, and the like. Cycloalkyls are also referred to herein as “carbocyclic” rings systems, and include bi- and tri-cyclic ring systems having from 8 to 14 carbon atoms such as

a cycloalkyl (such as cyclopentane or cyclohexane) fused to one or more aromatic (such as phenyl) or non-aromatic (such as cyclohexane) carbocyclic rings.

“Halogen” means fluorine, chlorine, bromine or iodine.

“Keto” means a carbonyl group (*i.e.*, =O).

5 “Aryl” means an aromatic carbocyclic moiety such as-phenyl or naphthyl.

“Arylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with an aryl moiety, such as benzyl, -(CH₂)₂phenyl, -(CH₂)₃phenyl, -CH(phenyl)₂, and the like.

10 “Heteroaryl” means an aromatic heterocycle ring of 5- to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono- and bicyclic ring systems. Representative heteroaryls are pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, 15 phthalazinyl, and quinazolinyl.

“Heteroarylalkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heteroaryl moiety, such as -CH₂pyridinyl, -CH₂pyrimidinyl, and the like.

“Heterocycle” means a heterocyclic ring containing from 5 to 10 ring atoms

20 “Heterocycle” means a 5- to 7-membered monocyclic, or 7- to 10-membered bicyclic, heterocyclic ring which is either saturated, unsaturated, or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized, including bicyclic rings in which any of the above heterocycles are fused to a benzene ring. The heterocycle may be attached via any 25 heteroatom or carbon atom. Heterocycles include heteroaryls as defined above. Thus, in addition to the heteroaryls listed above, heterocycles also include morpholinyl, pyrrolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuran, tetrahydropyran, tetrahydropyridinyl, tetrahydroprimidinyl, tetrahydrothiophenyl, tetrahydrothiopyran, tetrahydropyrimidinyl, tetrahydrothiophenyl, 30 tetrahydrothiopyran, and the like.

“Heterocyclealkyl” means an alkyl having at least one alkyl hydrogen atom replaced with a heterocycle, such as -CH₂morpholinyl, and the like.

The term “substituted” as used herein means any of the above groups (*i.e.*, aryl, arylalkyl, heterocycle and heterocyclealkyl) wherein at least one hydrogen atom is 35 replaced with a substituent. In the case of a keto substituent (“C(=O)”) two hydrogen atoms

are replaced. Substituents include halogen, hydroxy, alkyl, substituted alkyl (such as haloalkyl, mono- or di-substituted aminoalkyl, alkyloxyalkyl, and the like, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -NR_aR_b, -NR_aC(=O)R_b, -NR_aC(=O)NR_aR_b, -NR_aC(=O)OR_b, 5 -NR_aSO₂R_b, -OR_a, -C(=O)R_a-C(=O)OR_a-C(=O)NR_aR_b, -OC(=O)R_a, -OC(=O)OR_a, -OC(=O)NR_aR_b, -NR_aSO₂R_b, or a radical of the formula -Y-Z-R_a where Y is alkanediyl, substitute alkanediyl, or a direct bond, Z is -O-, -S-, -S(=O)-, -S(=O)₂-, -N(R_b)-, -C(=O)-, 10 -C(=O)O-, -OC(=O)-, -N(R_b)C(=O)-, -C(=O)N(R_b)- or a direct bond, wherein R_a and R_b are the same or different and independently hydrogen, amino, alkyl, substituted alkyl (including halogenated alkyl), aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, 15 substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl, or wherein R_a and R_b taken together with the nitrogen atom to which they are attached form a heterocycle or substituted heterocycle.

“Haloalkyl” means alkyl having one or more hydrogen atoms replaced with 15 halogen, such as -CF₃.

“Hydroxyalkyl” means alkyl having one or more hydrogen atoms replaced with hydroxy, such as -CH₂OH

“Sulfonylalkyl” means -SO₂-(alkyl);

“Sulfinylalkyl” means -SO-(alkyl);

20 “Thioalkyl” means -S-(alkyl);

“Carboxyl” means -COOH.

“Alkoxy” means -O-(alkyl), such as methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butyloxy, iso-butyloxy, and the like.

“Patient” means an animal, including, but not limited to, an animal such as a 25 cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, and guinea pig, and is more preferably a mammal, and most preferably a human.

“Acyl” means alkyl(C=O)


“ClH” means the hydrochloride salt of compounds depicted by their chemical 30 structure.

“Nitrogen-containing non-aromatic heterocycle” means morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, hydantoinyl, tetrahydropyrindinyl, tetrahydropyrimidinyl, oxazolidinyl, thiazolidinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and the like.

35


The anilinopyrimidine derivatives can generally be obtained using organic synthesis techniques known to those skilled in the art, as well as by the following general techniques and the procedures set forth in the Examples. To that end, the anilinopyrimidine derivatives can be made according to the following Reaction Schemes 1 through 9:

5

Reaction Scheme 1

15

20




25

30




Appropriately substituted methylketones may be treated with a dimethylformamide acetal, such as dimethylformamide dimethylacetal or dimethylformamide diethylacetal, to afford the corresponding β -dimethylaminobutenones. Treatment of the aminobutenones with thiourea in the presence of a base such as sodium methoxide, followed by alkylation with an alkyl halide, such as methyl iodide, gives 4-substituted 2-alkylthiopyrimidines. Oxidation of the thioether with organic and inorganic oxidizing agents, such as m-chloroperbenzoic acid or oxone, yields the sulfones which, upon condensation with *p*-aminocarbonylanilines, give rise to the formation of the desired anilinopyrimidine derivatives.

Reaction Scheme 2

35




Similarly, the anilinopyrimidine derivatives may be prepared from the 2-chloropyrimidine derivatives. Thus, condensation of the β -dimethylaminobutenones with 15 urea followed by the treatment with chlorinating agent such as phosphorus oxychloride gives 4-substituted 2-chloropyrimidines. Further treatment with substituted anilines affords the desired anilinopyrimidine derivatives.




15 The aminopyrimidine derivatives can also be prepared by condensation of the β -dimethylaminobutenones with appropriately substituted guanidines. The requisite guanidines may be synthesized by the reaction of the aniline with cyanamide in the presence of an acid, or with a pyrazoloamidine.

20 Reaction Scheme 4




35 Cyclization of alkoxy carbonyl phenyl guanidines with the β -aminoketones gives 4-substituted 2-(4-carboxyphenyl) aminopyrimidines. Condensation of the benzoic acid derivatives with appropriate amines affords the desired amides.

Reaction Scheme 5




Condensation of the benzoic acids with N-Boc-piperazine followed by deprotection of the tert-butoxycarbonyl group with an acid such as hydrochloric acid yields piperazineamides. Subsequent condensation with carboxylic acid derivatives yields bis-acylpiperazines.

Reaction Scheme 6




Similar reaction with sulfonyl chlorides gives the corresponding sulfonamides.

Reaction Scheme 7




Acetophenones with p-alkyl- and arylthio groups may be prepared by the reaction of p-chloroacetophenone with alkyl and arylthiols.

Reaction Scheme 8

Anilinopyrimidines with the p-alkyl- and arylsulfenyl groups may be prepared

10 by controlled oxidation of the sulfides with an oxidizing agent such as oxone.

Reaction Scheme 9

Anilinopyrimidine derivatives having p-alkyl- and arylsulfonyl groups may be prepared by oxidation of the sulfides with an oxidizing agent such as oxone.

The anilinopyrimidine derivatives can be in the form of a pharmaceutically acceptable salt or free base. Acid addition salts of the free base can be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic acetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Additional salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate, and pamoate (*i.e.*,

35


1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. The term "pharmaceutically acceptable salt" is intended to encompass any and all acceptable salt forms.

Pharmaceutically acceptable salts can be formed by conventional and known techniques, such as by reacting a compound of this invention with a suitable acid as disclosed above. Such salts are typically formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash in the final step of the synthesis. The salt-forming acid may dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the anilinopyrimidine derivative is desired in the free base form, it may be isolated from a basic final wash step, according to known techniques. For example, a typical technique for preparing hydrochloride salt is to dissolve the free base in a suitable solvent, and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it.

The anilinopyrimidine derivatives can also exist in various isomeric forms, including configurational, geometric and conformational isomers, as well as existing in various tautomeric forms, particularly those that differ in the point of attachment of a hydrogen atom. As used herein, the term "isomer" is intended to encompass all isomeric forms of a compound, including tautomeric forms of the compound.

As used herein, the term "prodrug" refers to any derivative of the anilinopyrimidine derivatives that are metabolized or otherwise converted into an active form upon introduction into the body of an animal. Prodrugs are well known to those skilled in the art of pharmaceutical chemistry, and provide benefits such as increased adsorption and half-life. Prodrugs of this invention may be formed when, for example, hydroxy groups are esterified or alkylated, or when carboxyl groups are esterified. Those skilled in the art of drug delivery will readily appreciate that the pharmacokinetic properties of anilinopyrimidine derivatives may be controlled by an appropriate choice of moieties to produce prodrug derivatives.

In another embodiment, the present invention provides a method for treating or preventing a condition responsive to JNK pathway inhibition, comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative having the formula of structure (I):



including isomers, prodrugs and pharmaceutically acceptable salts thereof,

wherein

- 10 R_1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R_7 ;
- 15 R_2 and R_3 are the same or different and are independently hydrogen or lower alkyl;
- 15 R_4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;
- 20 R_5 and R_6 are the same or different and independently $-R_8$, $-(CH_2)_aC(=O)R_9$, $-(CH_2)_aC(=O)OR_9$, $-(CH_2)_aC(=O)NR_9R_{10}$, $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$, $-(CH_2)_aNR_9C(=O)R_{10}$, $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$, $-(CH_2)_aNR_9R_{10}$, $-(CH_2)_aOR_9$, $-(CH_2)_aSO_cR_9$ or $-(CH_2)_aSO_2NR_9R_{10}$;
- 25 or R_5 and R_6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;
- 25 R_7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_cR_8$, $-SO_cNR_8R_9$, $-NR_8SO_cR_9$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;
- 30 R_8 , R_9 , R_{10} and R_{11} are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;
- 35

or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;
a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and
5 c is at each occurrence 0, 1 or 2.

In another embodiment, the present invention provides a method for treating or preventing an inflammatory or autoimmune condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

10 In another embodiment, the present invention provides a method for treating or preventing a cardiovascular, metabolic or ischemic condition comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

In another embodiment, the present invention provides a method for treating or preventing an infectious disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

15 In another embodiment, the present invention provides a method for treating or preventing cancer comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

20 In another embodiment, the present invention provides a method for treating or preventing stroke, epilepsy, Alzheimer's disease comprising administering to a patient in need thereof an effective amount of an anilinopyrimidine derivative.

25 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I), R₁ is a substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not pyridyl. When R₁ is substituted, it is substituted with one or more substituents defined above. Preferably, when substituted, R₁ is substituted with a halogen, sulfone or sulfonamide.

30 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl or quinazolinyl.

35 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl or heteroaryl with the proviso that the heteroaryl is not imidazo[1,2-a]pyrid-3-yl or pyrazolo[2,3-a]pyrid-3-yl. When R₁ is substituted, it is substituted with one or more substituents defined above. Preferably, when substituted, R₁ is substituted with a halogen, sulfone or sulfonamide.

In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I), R₁ is substituted or unsubstituted aryl, preferably phenyl or naphthyl. When R₁ is a substituted aryl, it is substituted with one or more substituents defined above. Preferably, when substituted, R₁ is substituted with a halogen, sulfone or sulfonamide.

5 In another embodiment of the present methods, in the anilinopyrimidine derivatives of structure (I), R₅ and R₆ taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted nitrogen containing non-aromatic heterocycle.

10 In another embodiment of the present methods, the nitrogen-containing non-aromatic heterocycle is piperazinyl, piperadinyll or morpholinyl. When the nitrogen-containing non-aromatic heterocycle is a substituted piperazinyl, piperadinyll or morpholinyl ring, the substituents are defined above. Preferably, when substituted, the substituent is alkyl, amino, alkylamino, alkylether, acyl, pyrrolidinyl or piperidinyl.

15 When used in the present methods, the anilinopyrimidine derivatives of this invention can be administered as a component of a composition that optionally comprises a pharmaceutically acceptable carrier or vehicle.

20 Conditions that may be treated using an anilinopyrimidine derivative, or using a pharmaceutical composition containing the same, include any condition that is responsive to JNK pathway inhibition, and thereby benefit from administration of such an inhibitor. In general, the anilinopyrimidine derivatives of this invention may be used for the prevention and/or treatment of an inflammatory or autoimmune condition, a cardiovascular, metabolic or ischemic condition, an infectious disease or cancer. Representative conditions in this regard include (but not limited to) rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, Huntington's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, multiple sclerosis, lupus erythematosus, Type II diabetes, 25 osteoporosis, erectile dysfunction, atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, myocardial infarction, stroke, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, multiple organ failure, psoriasis, eczema, dermatitis, epilepsy, Alzheimer's disease, Parkinson's disease, Lou Gerig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip, viral infections (e.g., those caused by human 30 immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papillomavirus, human T-

cell leukemia virus or Epstein-Bar virus), cachexia, and cancers of a variety of tissues such as colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, urinary bladder, ovary, bone marrow, thymus, breast, bone and uterine.

5 The anilinopyrimidine derivatives can also be used in cancer adjuvant therapy in combination with a cytotoxic agent or with radiation therapy.

Compounds and compositions of the present invention, including isomers, prodrugs and pharmaceutically acceptable salts thereof, are particularly useful in the treatment and/or prevention of Lou Gehrig's disease, acute respiratory distress syndrome, 10 osteoarthritis, chronic obstructive pulmonary disease, left ventricular hypertrophy, myocardial infarction, ischemic diseases of heart, kidney, liver and brain, stroke, epilepsy and Parkinson's disease.

The anilinopyrimidine derivatives can be administered to a patient orally or parenterally in conventional and well known preparations, such as capsules, microcapsules, 15 tablets, granules, powder, troches, pills, suppositories, injections, suspensions and syrups.

Prior to administration, the anilinopyrimidine derivatives are typically formulated as a pharmaceutical composition that contains an effective dosage amount of one or more of such compounds in combination with one (or more) pharmaceutically acceptable carrier(s).

Suitable formulations in this regard may be prepared by methods commonly employed using 20 conventional, organic or inorganic additives, such as an excipient (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate), a binder (e.g., cellulose, methylcellulose, hydroxymethyl cellulose, polypropylpyrrolidone, polyvinylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose or starch), a disintegrator (e.g., starch, carboxymethylcellulose, hydroxypropylstarch, low substituted 25 hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous sicilic acid, talc or sodium lauryl sulfate), a flavoring agent (e.g., citric acid, menthol, glycine or orange powder) a preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodium citrate or acetic acid), a suspending agent (e.g., methylcellulose, polyvinyl 30 pyrrolidone or aluminum stearate), a dispersing agent (e.g., hydroxypropylmethylcellulose), a diluent (e.g., water), and/or a base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol).

The dose of an anilinopyrimidine derivative to be administered to a patient, such as a human, is rather widely variable and subject to the judgment of the attending 35 physician. The general range of effective administration rates of the anilinopyrimidine

derivatives are from about 0.05 mg/day to about 250 mg/day, and typically from about 0.25 mg/day to 60 mg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation use, subject condition (such as weight), and/or the route of administration.

Further, the effect of the anilinopyrimidine derivatives can be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the anilinopyrimidine derivative may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

In certain embodiments, the anilinopyrimidine derivatives can be used in combination, e.g., as an adjunct therapy, with at least one other therapeutic agent. An anilinopyrimidine derivative and the other therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, an anilinopyrimidine derivative is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as or in a different composition from that comprising the anilinopyrimidine derivative. In another embodiment, an anilinopyrimidine derivative is administered prior or subsequent to administration of another therapeutic agent. As many of the disorders for which the anilinopyrimidine derivatives are useful in treating are chronic, in one embodiment combination therapy involves alternating between administering an anilinopyrimidine derivative and another therapeutic agent. The duration of administration of the anilinopyrimidine derivative or the other therapeutic agent can be, e.g., one month, three months, six months, a year, or for more extended periods, such as the patient's lifetime. In certain embodiments, when a composition of the invention is administered concurrently with another therapeutic agent that potentially produces adverse side effects including, but not limited to, toxicity, the other therapeutic agent can advantageously be administered at a dose that falls below the threshold at which the adverse side effect is elicited.

The other therapeutic agent can be an anti-inflammatory agent. Useful anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid,

meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetone, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide; leukotriene antagonists
5 including, but not limited to, zileuton, aurothioglucose, gold sodium thiomalate and auranofin; and other anti-inflammatory agents including, but not limited to, colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone. Anti-inflammatory agents particularly useful for treating arthritis, including rhumatiod arthritis, include enbrel, infliximab, anakinra, celecoxib and rofecoxib.

10 The other therapeutic agent can be an anti-cancer agent. Useful anti-cancer agents include, but are not limited to, nitrogen mustards, such as cyclophosphamide, Ifosfamide, trofosfamide and Chlorambucil; nitrosoureas, such as carmustine (BCNU) and Lomustine (CCNU); alkylsulphonates, such as busulfan and Treosulfan; triazenes, such as Dacarbazine; platinum-containing compounds, such as Cisplatin and carboplatin; vinca
15 alkaloids, such as vincristine, Vinblastine, Vindesine and Vinorelbine; taxoids, such as paclitaxel and Docetaxol; epipodophyllins, such as etoposide, Teniposide, Topotecan, 9-aminocamptothecin, camptothecin and crizotinib; mytomycins, such as mytomycin C; DHFR inhibitors, such as methotrexate and Trimethoprim; IMP-dehydrogenase inhibitors, such as mycophenolic acid, Tiazofurin, Ribavirin and EICAR; ribonucleotide-reductase
20 inhibitors, such as hydroxyurea and deferoxamine; uracil analogs, such as 5-fluorouracil, Flouxuridine, Doxifluridine and Ratitrexed; cytosine analogs, such as cytarabine (ara C), cytosine arabinoside and fludarabine; purine analogs, such as mercaptopurine and thioguanine; anti-estrogens, such as Tamoxifen, Raloxifene and megestrol; LHRH agonists, such as goserelin and Leuprolide acetate; anti-androgens, such as flutamide and
25 bicalutamide; vitamin D3 analogs, such as B 1089, CB 1093 and KH 1060; photodynamic therapeutic agents, such as verteporfin (BPD-MA), Phthalocyanine, photosensitizer Pc4 and demethoxyhypocrellin A (2BA-2-DMHA); cytokines, such as interferon- α , interferon- γ and tumor-necrosis factor; isoprenylation inhibitors, such as Lovastatin; dopaminergic neurotoxins, such as 1-methyl-4-phenylpyridinium ion; cell-cycle inhibitors, such as
30 staurosporine; actinomycins, such as Actinomycin D and Dactinomycin; bleomycins, such as bleomycin A2, Bleomycin B2 and Peplomycin; anthracyclines, such as daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin and Mitoxantrone; MDR inhibitors, such as verapamil; and Ca^{2+} ATPase inhibitors, such as thapsigargin.

The following examples are offered by way of illustration, not limitation. To
35 this end, it should be noted that one or more hydrogen atoms may be omitted from the drawn

structure consistent with accepted shorthand notation of such organic compounds, and that one skilled in the art would readily appreciate their presence.

Retention time data for the following examples was obtained by one of two methods detailed as follows:

5 Method A

Column: YMC Pro C-18, 3.0 μ spherical silica gel, 4.0 x 50 mm, pore size 120 \AA .

Gradient: 0-10 min, 20%A - 90%A linear binary gradient.

Flow rate: 2.0 mL/min.

Mobile Phase: A, 0.1% formic acid in acetonitrile; B, 0.1% trifluoroacetic acid in water.

10

Method B

Column: YMC ODS-A, 5.0 μ spherical silica gel, 4.6 x 250 mm, pore size 120 \AA .

Gradient: 0-10 min, 20%A - 90%A linear binary gradient followed by 10-25 min, 100%A.

15 Flow rate: 1.0 mL/min.

Mobile Phase: A, 0.1% trifluoroacetic acid in acetonitrile; B, 0.1% trifluoroacetic acid in water.

EXAMPLES


20

EXAMPLE 1

SYNTHESIS OF

4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO} BENZAMIDE

25



30

(2E)-3-(Dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one

A solution of 1-(4-chlorophenyl)ethan-1-one (3.0g, 19.3 mmol) and N,N-dimethylformamide diisopropylacetal (20ml) was heated at 150°C for 16 hours. The reaction mixture was cooled to 0°C and treated with hexanes (20ml). The resulting solid

35

was collected via filtration and washed with hexanes to provide the title compound: EI-MS (m/z) 209 [M+I]⁺.

4-(4-Chlorophenyl)pyrimidine-2-thiol

5 To a solution of (2E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one (1.5g, 7.2 mmol) in ethanol (25 ml) was added thiourea (0.60g, 7.9 mmol) and potassium carbonate (K_2CO_3) (1.19g, 8.63 mmol). The resulting suspension was heated to 85°C for 12 hours then cooled to ambient temperature. The resulting solid was collected and thoroughly washed with water and hexanes to provide a beige solid: EI-MS (m/z) 222 [M+I]⁺.

10 4-(4-Chlorophenyl)-2-methylthiopyrimidine

15 4-(4-Chlorophenyl)pyrimidine-2-thiol (1.2 g, 5.39 mmol) was taken in 10 ml of an aqueous potassium hydroxide (0.453g, 5.39 mmol) solution. Iodomethane (503 μ l, 5.39 mmol) was added at ambient temperature and the reaction mixture was allowed to stir for 30 minutes. The resulting white solid was collected via filtration and washed with minimal water and hexanes to provide the title compound: EI-MS (m/z) 237 [M+I]⁺.

4-(4-chlorophenyl)-2-(methylsulfonyl)pyrimidine

20 To a solution of 4-(4-chlorophenyl)-2-methylthiopyrimidine (1.1 g, 4.65 mmol) in acetone (30 ml) and water (10 ml) was added oxone (7.14g, 11.62 mmol). The reaction mixture was stirred for 18 hours then diluted with water and extracted into dichloromethane. The extracts were dried over magnesium sulfate, filtered and concentrated to provide a white solid: EI-MS (m/z) 269 [M+I]⁺.


25 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzamide}

30 To a solution of 4-(4-chlorophenyl)-2-(methylsulfonyl)pyrimidine (0.10g, 0.37 mmol) and 4-aminobenzamide in 2-propanol (3 ml) was heated to 120°C in a sealed vessel for 14 hours. The crude material was concentrated and purified by preparative HPLC to provide the title compound as a beige solid: LC/MS Retention Time; 6.30 min (Method A), M+I; 325.

EXAMPLE 2

35 ALTERNATIVE SYNTHESIS OF

4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZAMIDE

N-{(4-Aminocarbonyl)phenyl}guanidine nitrate

10 To a stirred suspension of 4-aminocarbonylaniline (20 g, 147 mmol) and cyanamide (14.2g, 338 mmol) in 70 mL of ethanol was added concentrated nitric acid (20 mL) dropwise. The reaction mixture was heated at reflux overnight, and cooled. Volatile matters were evaporated to give a thick oil. The residue was taken up in methylene chloride and methanol to afford yellow solid. This material was filtered, washed with ether and water and dried in vacuo at 50°C to afford the desired product (17.5 g, 66% yield): LC/MS
15 Retention Time; 0.63 min (Method A), M+1; 179.

4-{{4-Chlorophenyl)pyrimidin-2-yl]amino}benzamide

20 To a solution of (2E)-3-(dimethylamino)-1-(4-chlorophenyl)prop-2-en-1-one (0.10 g, 0.48 mmol), 4-(amidinoamino)benzamide nitrate (0.116 g, 0.48 mmol), and potassium carbonate (0.132g, 0.96 mmol) in ethanol (10 ml) was heated to 120°C overnight in a sealed vessel. The reaction mixture was cooled to room temperature and the resulting solid was collected then washed with ethanol, water, and diethyl ether to provide the title compound as a beige solid, identical in all respects with the compound prepared in
25 Example 1.

30

35





EXAMPLE 3

SYNTHESIS OF REPRESENTATIVE COMPOUNDS

The compounds listed below were prepared according to the procedure of Example 2 using the appropriate methylketone as the starting material.




5

	Compound Number	Structure	MOL. WEIGHT	RT, min	M+1
10	3-1		315.335	5.67	316
15	3-2		296.353	5.53	296
20	3-3		324.314	5.93	325
25	3-4		290.325	5.77	291
30	3-5		320.35	6.07	321
35					

3-6		279.302	4.8	280
3-7		464.931	6.47	4.65
3-8		431.474	5.53	432
3-9		431.474	5.58	432

30




35

3-10		449.576	4.62	450
3-11		407.539	4.62	408
3-12		462.619	4.47	463

25




30

35

3-22		369.221	6.88	369
3-23		335.365	5.8	336
3-24		321.339	5.5	322

30

35

3-25		334.381	4.04	335
3-26		373.458	5.57	374
3-27		335.322	5.87	336




30

35

3-28		362.431	6.77	363
3-29		333.393	5.07	334
3-30		375.43	5.47	376

30




35




5	3-31		359.215	6.57	359
10	3-32		359.215	6.47	359
15	3-33		374.321	6.43	375

25

30




35

3-34		340.384	6.33	341
3-35		411.487	6.73	412
3-36		356.387	4.27	357

3-37		338.797	6.37	339
3-38		377.205	6.50	377
3-39		393.66	6.67	393

30

35

3-40		334.334	4.7	335
3-41		330.346	11.17 6	331
3-42		346.413	10.28 8	347





30





35

30

35

5	3-46		477.5372	12.74	478.3
10	3-47		443.5481	11.29 2	444.6
15	3-48		485.4638	11.39 6	486.3
20	3-49		486.573	8.548	487.3
25					
30					

3-54		501.5308	12.07 2	502.3
3-55		444.5362	8.696	445.4
3-56		500.3498	9.74	428.4
3-57		480.3638	11.08 4	482.2

	3-58		457.5749	12.34 4	458.3
5	3-59		500.5998	9.924	501.5
10	3-60		368.8223	10.62 4	369.2
15	3-61		564.6428	6.49	565.4
20					
25					
30					

3-62		415.4945	10.26 8	416.3
3-63		470.3579	12.05	470.3


20

EXAMPLE 4


SYNTHESIS OF 4-[(4-{4-[(4-CHLOROPHENYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE

25

30



35




To a stirred solution of *p*-chlorobenzenethiol (**1**) (3.2g, 0.022 mol) in DMF (40 mL) was added NaH (60% dispersion in mineral oil, 0.8g). After the effervescence had ceased, *p*-chlorobenzenethiol (0.011 mol, 0.55 equiv) was added. The solution was then stirred at 110 °C for 3 h. The mixture was cooled to room temperature and then diluted with ether (150 mL). The ethereal suspension was washed with 5% NaOH (aq, 50 mL), 3% HCl (aq, 2 x 50 mL), filtered, and concentrated to afford 2.88 g of *p*-chlorophenylthioacetophenone (**2**) (100%). Biarylsulfide (**2**) was then dissolved in acetone/water (4:1, v/v, 100 mL). OXONE (13.5 g, 2.2 equiv) was added to the solution. The reaction was stirred 4 h at room temperature. After this time, the acetone was removed *in vacuo*. The mixture was diluted in ether (100 mL) and water (100mL). The mixture was shaken and the layers separated. The ether layer was dried (MgSO_4), filtered, and concentrated to afford 2.02 g (62%) of sulfone **3**. Sulfone (**3**) was then dissolved in dimethylformamide dimethyl acetal (15 mL) and heated to 110 °C for 12 h. The reaction mixture was then concentrated to remove excess in dimethylformamide dimethyl acetal. A

portion of the intermediate ene-amino ketone (0.38 g, 1.09 mmol) was taken up in ethanol (20 mL). To this solution was added K_2CO_3 (0.45 g, 3 equiv) and 4-guanadinobenzamide (4) (0.26 g, 1 equiv). The reaction mixture was heated in a sealed tube at 100°C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then 5 filtered. The solid was washed with water and ethanol. A portion of the material was purified by preparatory HPLC to afford 15 mg of the desired compound, which was found to be 100% pure by analytical HPLC. LCMS ($M+H=465.0$ @ 6.47 min.(Method A)).

EXAMPLE 5

10 **SYNTHESIS OF 4-($\{4$ -[4-(4-PYRIDYLSULFONYL)PHENYL]PYRIMIDIN-2-YL}AMINO)BENZAMIDE**

15



20


The above compound was made according to the procedure of Example 4
25 from 2-mercaptopypyridine and the appropriate thiol as the starting materials. LCMS:
($M+H=432.1$, @ 5.50 min.(Method B)).

30

35

EXAMPLE 6SYNTHESIS OF 4-(*{*4-[4-(2-PYRIDYLSULFONYL)PHENYL]*}*PYRIMIDIN-2-YL*{*AMINO*}*BENZAMIDE

5



10

15

The above compound was made according to the procedure of Example 4 from 2-mercaptopypyridine and the appropriate thiol as the starting materials. LCMS ($M+H=432.0 @ 5.58$ min.(Method B)).


EXAMPLE 7

20

SYNTHESIS OF 4-(*{*4-[4-(3-PYRIDYLSULFONYL)PHENYL]PYRIMIDIN-2-YL*{*AMINO*}*BENZAMIDE

25


30



The above compound was made according to the procedure of Example 4 from 3-mercaptopypyridine and the appropriate thiol as the starting materials. LCMS ($M+H=432.1 @ 5.55$ min.(Method B)).

EXAMPLE 8SYNTHESIS OF 4-(*{*4-[4-(3-HYDROXYPROPYLTHIO)PHENYL]PYRIMIDIN-2-YL}AMINO)BENZAMIDE

5




10

15 The above compound was made according to the procedure of Example 4 from 3-mercaptopropanol and the appropriate thiol as the starting materials. LCMS (M+H=381.0 @ 5.55 min.(Method B)).


EXAMPLE 920 SYNTHESIS OF 4-[*{*4-[*{*(3-HYDROXYPROPYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL}AMINO]BENZAMIDE

25




30

35



5

10



25

30

35


To a solution of 3-mercaptopropanol (5 g, 0.054 mol) in DMF (40 mL) was added NaH (2.2 g, 60% dispersion in mineral oil). After the bubbling had ceased, *p*-chloroacetophenone (5.25 mL, 0.041 mol, 0.75 equiv) was added and the mixture was stirred at 100°C for 3 h. The reaction was cooled, diluted with ether (200 mL), and washed with 5% HCl (aq) (2 x 30 mL), water (2 x 50 mL), and then brine (40 mL). The ether layer was dried (MgSO_4), filtered, and concentrated to afford thioaryl ketone (5) (6.1 g, 0.29 mol, 72%). Ketone (5) (0.72 g, 3.4 mmol) was dissolved in acetone/water (4:1 v/v, 20 mL). OXONE® (4.2 g) was added and the mixture was stirred for 2 h. The mixture was then concentrated, diluted with ether (75 mL), washed with water (3 x 50 mL), and then brine (50 mL). The ether layer was then dried (MgSO_4), filtered, and concentrated to afford to aryl sulfone (6). The title compound was prepared as previously described in Example 4 from

ketone (**6**) to afford 39 mg (3%) of analytically pure material. LCMS: (M+H=413.0 @ 5.04 min. (Method A)).

5

EXAMPLE 10SYNTHESIS OF 4-(*{*4-[4-(3-MORPHOLIN-4-YLPROPYLTHIO)PHENYL]PYRIMIDIN-2-YL}AMINO)BENZAMIDE


10




15

20


25



30



35



Acetophenone (**5**) was then taken up on toluene (50 mL). To this solution was added ethylene glycol (2.6 mL, 2 equiv) and *p*-toluenesulfonic acid (0.7g). The reaction was refluxed with a Dean Stark trap for 2 - 3 h. After azeotropic removal of water, the reaction was cooled and then washed with 10% NaHCO₃ (aq, 50 mL), water (50 mL), and brine (50 mL). The organic extract was dried (MgSO₄), filtered, and concentrated. The crude acetal was then taken up in CH₂CL₂ (20 mL). In a separate flask, (COCl)₂ (2.26 mL, 26.0 mmol) was dissolved in CH₂CL₂ (20 mL) and cooled to -78 °C. DMSO (3.7 mL, 52.0 mmol) in CH₂CL₂ (5 mL) was then added to the cold solution dropwise. This mixture was stirred for 2 min, after which the crude acetal was added in CH₂CL₂ (20 mL). After stirring 15 min, Et₃N (16.5 mL, 5 equiv) was added slowly. The resulting mixture was stirred 5 min, and then let warm to room temperature over 1 h. The mixture was then poured into a separatory funnel and washed with 5% NaHCO₃ (100 mL). The organic layer was then washed with brine (50 mL), dried (Na₂SO₄), filtered, and concentrated to afford crude aldehyde (**7**). Aldehyde (**7**)(0.5 g) was then taken up in MeOH/AcOH (10 mL). To this solution was added morpholine (0.21 mL). The mixture was stirred 10 min, after which time NaBH₃CN (0.19 g) was added. After 30 min, the reaction mixture was concentrated, basified with 3 M NaOH, and extracted with CH₂CL₂ (3 x 15 mL). The organic extracts

were concentrated and then taken up in acetone/water (9:1 v/v, 20 mL). *P*-TsOH (0.1 g) was then added to the solution and the mixture was stirred 12 h. After this time, the mixture was concentrated, basified with 1 M NaOH, and extracted with CH₂Cl₂ (3 x 15 mL). The organic extracts were then dried (Na₂SO₄), filtered, and concentrated to afford crude aryl
5 ketone (8), which was taken up in dimethylformamide dimethyl acetal (15 mL) and heated to 100°C for 12 h. The mixture was then concentrated down and taken up in EtOH (15 mL). To this solution was added K₂CO₃ (0.31 g) and 4-guanadinobenzamide (4) (0.14 g). The reaction mixture was heated in a sealed tube at 100°C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then filtered. The solid was
10 washed with water and ethanol. The material was purified by preparatory HPLC to afford the titled compound (33 mg, 4%): LCMS 4.62 min. (Method A), M+H = 450.

15

20

25


30

35

EXAMPLE 11

SYNTHESIS OF 4-[{(4-{4-[3-(DIMETHYLAMINO)PROPYLTHIO]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE

5



10

The titled compound was prepared by the procedure of Example 10, except
15 dimethylamine was used in place of morpholine during the reductive amination of aldehyde
(7). LCMS ($M+H=408.0$ @ 4.62 min.(Method B)).

20

25


30

35

EXAMPLE 12SYNTHESIS OF 4-[(4-{(4-METHYLPIPERAZINYL)PROPYLTHIO}PHENYL)PYRIMIDIN-2-YL)AMINO]BENZAMIDE

5

10



15

The titled compound was prepared by the procedure of Example 10, except N-methylpiperazine was used in place of morpholine in the reductive amination of aldehyde (7). LCMS ($M+H=463.0$ @ 4.47 min.(Method B)).

20


25

30

35


EXAMPLE 13SYNTHESIS OF 4-[4-{4-[(1-METHYL-4-PIPERIDYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL]AMINO]BENZAMIDE

5




10



15



20



25



30

4-mercaptopyridine (2.8 g, 25.0 mmol) was dissolved in DMF (25 mL). NaH (lg, 60% dispersion in mineral oil) was then added to the solution. After the effervescence had ceased, *p*-chloroacetophenone (1.4 mL, 11 mmol) was added and the mixture was

heated to 110 °C for 14 h. After this time, the mixture was cooled, diluted with ether (100 mL). The mixture was washed with 5% NaOH (2 x 50 mL), water (2 x 50 mL), and brine (50 mL). The ethereal extract was dried (MgSO_4), filtered, and concentrated. The resulting oil was purified by flash chromatography (9:1 to 7:3 hexanes/ethyl acetate gradient).

5 Concentration of the desired fractions afforded 1.37g (54%) of thioacetophenone (9).

Sulfide (9) (1.37 g) was then dissolved in acetone/water (9:1 v/v, 35 mL). To this solution was added OXONE® (7.4 g, 2 equiv). The mixture was stirred for 2 h. The mixture was then concentrated, neutralized with 10% NaHCO_3 , and extracted with CH_2Cl_2 (3 x 50 mL). The organic extracts were dried (Na_2SO_4), filtered, and concentrated to afford diarylsulfone

10 (10) (1.25 g, 80%). Sulfone (10) (0.53 g, 2.0 mmol) was dissolved in THF (7 mL). To this solution was added Super Hydride® (6.3 mL, 1 M in THF) at room temperature. The solution was stirred at room temperature for 1 h, followed by quenching with MeOH (0.6 mL). The mixture was then concentrated. The residue was taken up in 1 N HCl (50 mL).

The aqueous mixture was extracted with ether (3 x 50 mL). The organic layers were

15 discarded. The aqueous layer was basified and extracted with CH_2Cl_2 (3 x 15 mL). The organic layers were concentrated. The residue was taken up in AcOH/MeOH (1:1 v/v; 10 mL). CH_2O (37% aq, 1 mL) and NaBH_3CN (0.1 g) were added. The mixture was stirred 30 min. The mixture was then concentrated, basified with 10% NaOH (aq) and extracted with CH_2Cl_2 (3 x 15 mL). The organic extracts were dried (Na_2SO_4), filtered, and concentrated

20 to afford crude ketone (11). Aryl ketone (10) was refluxed in dimethylformamide dimethyl acetal (15 mL) and heated to 100 °C for 12 h. The mixture was then concentrated down and taken up in EtOH (15 mL). To this solution was added K_2CO_3 (0.31 g) and 4-

guanadinobenzamide (4) (0.14 g). The reaction mixture was heated in a sealed tube at 100 °C for 12 h. The mixture was then cooled to room temperature, diluted with water (30 mL), and then filtered. The solid was washed with water and ethanol. The material was


25 purified by preparatory HPLC to afford 6.0 mg (0.5% from sulfone (10)) of the title compound. LCMS ($\text{M} + \text{H} = 452$ @ 6.13 min.(Method A)).

EXAMPLE 14

SYNTHESIS OF 4-[{(4-{[(4-METHYLPIPERAZINYL)SULFONYL]PHENYL}PYRIMIDIN-2-YL)AMINO]BENZAMIDE}


5

10



15

20




N-Methylpiperazine (1.16 mL, 0.01 mol) was dissolved in CH_2Cl_2 (30 mL) and Et_3N (4.4 mL, 0.033 mol). The solution was cooled to 0°C and 4-acetylbenzenesulfon chloride (2.29 g, 0.01 mol) was added at once. The reaction was stirred for 15 min., poured into a separatory funnel, and extracted with water (3 x 20 mL) and then brine (10 mL). The organic layer was dried (Na_2SO_4), filtered, and concentrated to afford aryl ketone (12). Ketone (12) was carried on without purification to make the title compound as described in Example 13. An analytical sample was purified by preparatory HPLC (0.028 mg, 0.6 %): LCMS ($M+H=453.2$ @ 5.48 min.(Method A)).


35

EXAMPLE 15
 SYNTHESIS OF
 4-{2-[(4-CARBAMOYLPHENYL)AMINO]PYRIMIDIN-4-YL}
 BENZOIC ACID


5




10



15



20



25

30 A mixture of ethyl 4-acetylbenzoate (3.00 g, 15.62 mmol) and N,N-dimethylformamide dimethyl acetal (6.2 g, 52.10 mmol) was refluxed for 18 hours, cooled and concentrated to give ethyl 4-[(2E)-3-(dimethylamino)prop-2-enyl]benzoate quantitatively. A solution of ethyl 4-[(2E)-3-(dimethylamino)prop-2-enyl]benzoate, potassium carbonate (3.55 g, 25.74 mmol), and 4-(amidinoamino)benzamide (3.10 g, 12.87 mmol) in ETOH (120 mL) was refluxed for 18 hours. The mixture was cooled, filtered, and

35

washed with ETOH, water, then ether respectively to give ethyl 4-{2-[(4-carbamoylphenyl)amino]pyrimidin-4-yl}benzoate (2.60 g, 46 % yield). This compound was refluxed for 2 hours in ETOH (30 mL), water (20 mL), and NaOH (0.640 g, 16 mmol). The reaction mixture was cooled, acidified to pH 3, and filtered to give 1.00 gram (42 % yield) of
5 the titled compound. HPLC/ES-MS (20-100% acetonitrile); R.T. 4.7 min.(Method A) ;
(m/z) 335 [M+ 1]⁺.

10

15

20


25

30


35

EXAMPLE 16
 SYNTHESIS OF
 (4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}
 PHENYL)-N,N-DIMETHYL CARBOXAMIDE


5



10




20



25

30



35

4-Guanidino-benzoic Acid Methyl Ester

To a stirred suspension of 4-guanidino benzoic acid (20.0g, 93mmol) in methanol (600mL) was added thionyl chloride (12mL) drop wise. The reaction mixture was stirred at room temperature overnight. The reaction was concentrated *in vacuo* to give a white powder. The crude material was dissolved in dichloromethane and evaporated to provide the title compound as a white powder (17.95g, 100% yield): HPLC Retention Time; 1.27 min (Method A). M+1; 193.

(2E)-3-Dimethylamino-1-(4-chlorophenyl)prop-2-en-1-one

A solution of 1-(4-chlorophenyl)ethane-1-one (35.0g, 226 mmol) and N, N Dimethylformamide diisopropylacetal (35mL) was heated to reflux for 16 hours. The reaction mixture was cooled to room temperature and treated with hexanes (50mL). The resulting solid was collected via filtration and washed with hexanes to provide the title compound as a yellow solid (47.12g, 99% yield): HPLC Retention Time; 6.45 min (Method B). M+1; 209.

4-[4-(4-Chlorophenyl)-pyrimidin-2-ylamino]benzoic Acid

A Solution of 4-guanidino-benzoic acid methyl ester (17.95g, 93mmol), (2E) 3-dimethylamino-1-(4-chlorophenyl)prop-2-en-1-one (19.44g, 93mmol, and potassium carbonate (38.50g, 279mmol) in 1-propanol was heated to reflux for 24 hours. The reaction mixture was cooled to room temperature. The resulting solid was collected via filtration and washed with ethanol to provide the title compound which was used without further purification. EI MS(m/z) 339 [M+1]⁺. To a suspension of 4-[4-(4-chlorophenyl)-pyrimidin-2-ylamino]benzoic acid methyl ester in methanol (100mL) was added 5N NaOH (100mL). The reaction mixture was heated to reflux for 4 hours and then cooled to room temperature. The resulting solid was collected via filtration, washed with hexanes, and dried in vacuo to provide the title compound as a yellow solid (27.36g, 100% yield): HPLC Retention Time; 7.29 min (Method A). M+1; 325.

(4-{{[4-(4-Chlorophenyl)-pyrimidin-2-yl]amino} phenyl}-N,N-dimethyl carboxamide

To 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino} benzoic acid (200 mg, 0.615 mmol) is added thionyl chloride (4 mL) along with a catalytic amount of DMF at room temperature. The resulting suspension is then refluxed for a period of 1 hour resulting in a clear pale yellow solution which was concentrated in vacuo. To the flask was then added a solution of dimethylamine (615 μ L of a 2.0 M solution in THF, 1.23 mmol) and triethylamine (124 mg,


1.23 mmol) in tetrahydrofuran (4.5 mL). The solution was then stirred for 18 hours at room temperature, diluted with water (5 mL) and filtered. Purification of the remaining solid by preparative HPLC yielded the title compound. HPLC/ES-MS: RT 6.74 min.(Method A); (m/z) 353 [M+1]⁺.

5


EXAMPLE 17

SYNTHESIS OF FURTHER REPRESENTATIVE COMPOUNDS

10



15







20

Compounds listed below were prepared according to the above procedure:

Compound Number	Structure	MOL. WEIGH T	RT, min	M+1
17-1		366.85	7.02	367





35

5	17-2		352.823	6.74	353
10	17-3		338.797	6.43	339
15	17-4		442.948	7.97	443
20	17-5		428.921	7.83	429

25

30





35

5	17-6		418.857	7.53	419
10	17-7		435.312	7.80	436
15	17-8		435.312	7.80	436
20	17-9		401.855	6.82	402

25

30

35





17-10		401.855	6.82	402
17-11		414.894	7.67	415
17-12		416.866	6.87	417
17-13		400.867	7.53	401

20

25

30





35

17-14		444.92	7.40	445
17-15		430.893	7.50	431
17-16		460.919	7.60	461
17-17		443.936	5.97	444

25

30





35

5	17-18		397.274	6.77	397
10	17-19		429.909	5.07	430
15	17-20		408.887	6.1	409
20	17-21		432.913	4.53	433

25

30





35

5	17-22		409.875	5.57	410
10	17-23		449.983	4.73	450
15	17-24		382.849	6.17	383
20	17-25		382.849	6.1	383

25




30

35

5	17-26		382.849	6.17	383
10	17-27		408.887	6.28	409
15	17-28		394.86	5.87	395
20	17-29		542.617	5.9	543

30





35

17-30		594.649	5.86	595
17-31		408.524	5.58	409
17-32		548.708	5.89	549

25





30

35

5	17-33		491.613	5.32	492
10	17-34		543.645	6.73	544
15	17-35		421.922	5.92	422
20	17-36		493.992	8.04	494





30

35

5	17-37		449.933	11.2	450
10	17-38		420.922	7.7	421
15	17-39		414.894	7.8	415
20	17-40		482.891	8.1	483
25					

30





35





5	17-41		442.948	8.07	443
10	17-42		493.79	8	495
15	17-43		422.957	8.4	423
20	17-44		406.915	7.9	407

25

30

35

17-45		428.921	7.8	429
17-46		458.903	7.7	459
17-47		508	6.2	508
17-48		456.974	7.5	457

	17-49		474.946	6.7	475
5					
10	17-50		467.954	6.7	468
15					
20	17-51		488.973	7.6	489
25					
30	17-52		550.888	8.5	551





30

35

17-53		505.018	7.8	505
17-54		449.94	5.9	450
17-55		420.941	8.2	421
17-56		442.948	8	443





30

35

5	17-57		432.953	8.2	433
10	17-58		404.855	7.5	405
15	17-59		482.891	8.1	483
20	17-60		504.971	7.6	505





30





35

5	17-61		432.884	7.8	433
10	17-62		463.366	8.1	463
15	17-63		428.921	7.9	429
20	17-64		458.903	7.8	460

30





35





5	17-65		472.93	7.8	473
10	17-66		420.941	8.1	421
15	17-67		474.946	7.8	475
20	17-68		483.784	8.2	483
25					
30					





5	17-69		438.913	7.8	439
10	17-70		432.884	7.1	433
15	17-71		392.888	7.8	393
20	17-72		396.876	7.2	397





30





35




5	17-73		474.946	7.8	475
10	17-74		463.366	8.2	463
15	17-75		442.948	8.1	443
20	17-76		444.92	7.8	445
30					

5	17-77		428.921	7.9	429
10	17-78		444.92	5.7	445
15	17-79		493.79	8	495
20	17-80		446.911	7.9	447

17-81		456.974	8.2	457
17-82		460.919	7.3	461
17-83		471.001	8.5	471
17-84		511.78	8.2	513




17-85		463.366	8	463
17-86		451.955	5.9	452
17-87		420.941	8.1	421
17-88		449.339	7.9	449

17-89		472.93	7.8	473
17-90		521.145	9.8	521
17-91		396.832	6.3	397
17-92		481.981	7.6	482

17-93		471.989	7.7	472
17-94		366.85	6.6	367
17-95		500.881	7.5	501

30

35

17-96		432.884	7.1	433
17-97		438.913	7.5	439
17-98		444.92	7.7	445




30

35

17-99		537.843	7.4	539
17-100		428.921	7.3	429
17-101		442.948	7.4	443

30




35





17-102		420.941	7.5	421
17-103		440.932	7.3	441
17-104		451.915	6.2	453




25

30

35

17-105			431.881	4.9	432	
17-106			396.876	5.71	397	
17-107			422.957	7.7	423	





17-108		465.038	8.6	465
17-109		483.784	7.8	483
17-110		456.974	7.7	457
17-111		456.974	7.6	457

17-112		511.78	7.4	513
17-113		449.339	7.4	449
17-114		483.784	7.8	485

25





30





35





5	17-115		392.888	7.1	393
10	17-116		446.911	7.2	447
15	17-117		378.861	6.8	379
20	17-118		429.909	4.9	430





30





35

5	17-119		440.892	6.5	441
10	17-120		408.872	6.5	409
15	17-121		440.892	6.4	441
20	17-122		415.882	4.9	416
30					

5	17-123		422.898	6.6	423
10	17-124		439.904	7.1	440
15	17-125		418.882	7.2	419
20	17-126		364.834	6.4	365
25					
30					





5	17-127		407.903	4.8	408
10	17-128		528.009	5.3	528
15	17-129		435.913	6.8	436
20	17-130		492.02	7.4	492
25					
30					





5	17-131		421.886	6.8	422
10	17-132		366.85	7.4	367
15	17-133		394.86	7.2	395
20	17-134		512.01	7.6	512
30					





5	17-135		499.999	7.8	500
10	17-136		516.987	7.9	515
15	17-137		465.939	7.4	466
20	17-138		407.884	7.2	408

30





35




17-139		450.924	7.4	451
17-140		468.986	8.3	469
17-141		493.008	7.1	493
17-142		437.929	4.6	438

5	17-143		537.971	8.3	538
10	17-144		390.872	7.7	391
15	17-145		437.929	4.6	438
20	17-146		465.038	8.4	465
25					
30					

17-147		443.936	6.3	444
17-148		470.962	6.3	473
17-149		487.964	8	488
17-150		486.016	6.3	486





17-151		443.936	6.3	444
17-152		435.956	4.6	436
17-153		437.972	4.7	438
17-154		409.919	4.6	410




17-155		458.947	7.4	365
17-156		364.834	7.2	365
17-157		428.921	7.9	429
17-158		469.974	8	470

5	17-159		487.945	6.3	488
10	17-160		449.94	5.8	450
15	17-161		484.988	4.4	485

30

35





5	17-162		463.966	6	464
10	17-163		449.94	5.8	450
15	17-164		464.998	4.8	465
20	17-165		443.936	5.6	444
25					
30					

5	17-166		349.78	7.3	350
10	17-167		422.914	12.167	423.0
15	17-168		392.888	6.983	393.2
20	17-169		476.021	8.92	476.2

25

30




35

	17-170		421.886	10.436	422.2
5	17-171		461.994	8.717	462.2
10	17-172		465.9822	8.45	466.9
15	17-173		407.903	9.38	408
20					

25

30





35

5	17-174		449.983	10.27	450
10	17-175		421.93	9.37	422
15	17-176		407.903	9.37	408
20	17-177		407.903	9.42	408

25

30

35



5	17-178		436.901	9.09	437
10	17-179		490.629	8.02	491
15	17-180		489.597	8.17	490
20	17-181		491.613	8.42	492

20

25

30

35





17-182		407.859	10.23	408
17-183		407.903	9.42	408
17-184		449.94	11.07	450
17-185		405.887	9.3	406

20

25

30

35





17-186		435.956	9.86	436
17-187		476.021	10.66	477
17-188		421.9296	10.63	422
17-189		469.9736	10.57	470

20

25





30

35

5	17-190		421.9296	
10	17-191		491.0359	9.03
15	17-192		465.9822	9.88
20	17-193		461.9942	10.48
25				462.3

30

35

17-194		451.9554	9.7	452.3
17-195		451.9554	9.7	452.3
17-196		505.0627	505.4	11.97 6
17-197		476.021	4.82	476.3

30





35





17-198	<chem>CC(=O)N1CCN(CCOCCOc2ccccc2)c3ccccc3c2nc4cc(Cl)ccccc4n3</chem>	481.981	4.35	482
17-199	<chem>CC(=O)N1CCN(CCOCCOC)c3ccccc3c2nc4cc(Cl)ccccc4n3</chem>	465.982	4.66	466.3
17-200	<chem>CC(=O)N1CCN(CC=CC)c3ccccc3c2nc4cc(Cl)ccccc4n3</chem>	433.941	4.59	434
17-201	<chem>CC(=O)N1CCN(CC2CCOC2)c3ccccc3c2nc4cc(Cl)ccccc4n3</chem>	477.993	4.63	478.3



30

35

17-202	<chem>CN(C)CCCN1CCN(C(=O)c2ccc3c(Nc4ccccc4Cl)nc3)CC1</chem>	479.025	0.79	479.3
17-203	<chem>CN1CCCC2C1CN(C(=O)c3ccc4c(Nc5ccccc5Cl)nc4)CC2</chem>	491.036	3.53	491.3
17-204	<chem>CCN(CC)C(=O)N1CCN(C(=O)c2ccc3c(Nc4ccccc4Cl)nc3)CC1</chem>	478.981	7.19	479.4
17-205	<chem>FC(F)c1ccc(CN2C(=O)N(C(=O)c3ccc4c(Nc5ccccc5Cl)nc4)CC2)cc1</chem>	545.015	6.86	553.4

17-206		556.067	7.23	556.4
17-207		508.019	7.9	508.4
17-208		574.381	5.89	465.4
17-209		630.444	3.56	631.3

5	17-210		614.445	5.64	505.4
10	17-211		406.871	5.86	436.4
15	17-212		477.9932	478.5	7.583
20	17-213		492.02	8.05	492.5
25					

17-214		476.021	8.817	476.5
17-215		437.92		438

15

20


25

30


35

EXAMPLE 18SYNTHESIS OF 4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZOIC
ACID PIPERAZINE AMIDE HYDROCHLORIDE

5



10




15

 $R^1 = 4\text{-chlorophenyl}$

Hydrogen chloride gas was bubbled slowly in a solution of tert-butyl 4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzoic acid piperazine amide (3.0 g, 6.1 mmol) in acetic acid (61 mL) for 20 minutes. The solution was concentrated and dried on a vacuum pump to give 2.6 g (99%) of the title compound; ES-MS, m/z 394 ($M+1$)⁺ LC/MS Retention Time, 5.84 min.(Method A).

EXAMPLE 19SYNTHESIS OF 4-{[4-(4-CHLOROPHENYL)PYRIMIDIN-2-YL]AMINO}BENZOIC
ACID 4-ETHYL PIPERAZINE AMIDE

30




A solution of 4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl piperazine ketone (0.5 g, 1.54 mmol), N-ethylpiperazine (0.18 g, 1.54 mmol), 1-(3-

dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (0.44 g, 2.31 mmol) and hydroxybenzotriazole (0.31 g, 2.31 mmol) in dimethylformamide (15 mL) was stirred for 18 h. Water (50 mL) was added and the solid was filtered. The solid was purified on preparatory HPLC (C-18 column, 30% acetonitrile to 100% acetonitrile in water-both containing 0.1% trifluoracetic acid) to give the titled compound, 0.27 g (42%) yield; ES-MS, m/z 422 (M+1)⁺ LC/MS Retention Time, 5.92 min.(Method A).

10 EXAMPLE 20

SYNTHESIS OF 4-ACYLAMINOPIPERIDINES



30 4-Aminopiperidyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl Ketone

Hydrochloride

(tert-Butoxy)-N-{1-[{(4-[(4-chlorophenyl)pyrimidin-2-yl]amino)phenyl]carbonyl}(4-piperidyl)carboxamide (4.00g, 7.87 mmol) was stirred in 50 mL EtOH followed by addition of anhydrous HCl gas. The reaction was stirred for 30 min. then concentrated down to a residue. To this was added a small amount of EtOH followed by dilution with ether. A yellow solid formed which was filtered and dried to give 3.00





grams of 4-aminopiperidyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl ketone hydrochloride: HPLC Retention time; 5.89 min. (Method B) M+1; 408.4

5 N-{1-[(4-{{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]-4-piperidyl}acetamide

Stirred 4-aminopiperidyl 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl ketone hydrochloride (300 mg , 0.582 mmol) in 10 mL THF with triethylamine (0.293 mg , 2.91 mmol). Acetic anhydride (89 mg , 0.873 mmol) was added and the reaction was stirred for 40 minutes. The solution was concentrated down and purified by preperative 10 HPLC to give N-{1-[(4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]-4-piperidyl}acetamide (0.120 g , 46 % yield): HPLC Retention time; 6.92 min. (Method B) M+1; 450.4



15 Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
20-1		449.94	6.92	450.4

5	20-2		531.013	7.49	531.4
10	20-3		518.039	7.6	518.4
15	20-4		521.018	7.19	521.4
20	20-5		478.981	7.18	479.4

30

35

20-6		479.965	7.3	480.2
20-7		541.052	7.68	541.4

15

20


25

30

35


EXAMPLE 21
SYNTHESIS OF PIPERAZINEACETIC ACID AMIDES

5




10

15



20

25



30 Ethyl 2-{4-[4-{[4-(4-Chlorophenyl)pyrimin-2-yl]amino}phenyl] carbonyl] piperazinyl}acetate

35 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzoic acid (5g, 15.3 mmol) was dissolved in dimethylformamide. The HOBT(2.82 g, 18.4 mmol) and EDCI(3.53 g, 18.4 mmol) were then added. The reaction stirred for 15 minutes then ethyl-2-piperazinylacetate (2.14 mL, 18.4 mmol) was added. The reaction was stirred overnight at

room temperature. Water (150 mL) was added. The solid was collected by filtration, and purified by silica-gel column chromatography (90% EtOAc/Hexane, Rt=0.25) to yield 4.3 g (45% yield) of ethyl 2-{4-[(4-{[4(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetate: HPLC Retention time; 9.932 min. (Method B) M+1; 480.2

5
5 2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl} acetic Acid

10 To ethyl 2-{4-[(4-{[4(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetate (5.0 g, 15.3 mmol) was added ethanol (69 mL) and NaOH (1.14 g, 29.2 mmol, 4.1 eq) in 46 mL water. The reaction was heated at 75°C for 1.5 hours. The reaction was acidified to pH=3, filtered, and dried, affording 4.3g of the acid 2-{4-[(4-{[4(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetic acid (83.3%): HPLC Retention time; 9.260 min. (Method B) M+1; 452.3

15







2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}N-ethylacetamide

20 2-{4-[(4-{[4-(4-Chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}acetic acid (0.200 g, 0.44 mmol) was dissolved in DMF then stirred for 15 minutes in ice-brine solution, then the HOBT (0.072 g, 0.53 mmol] then EDCI(0.102 g, 0.53 mmol) were added and stirred for another 30 minutes. Ethylamine (0.030 mL, 0.53 mmol) was added and the reaction was left to stir at room temp overnight. The reaction was quenched with 10 mL of water and a precipitate formed. The precipitate was colleted by filtration, and purified by preparative HPLC to yield 2-{4-[(4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperazinyl}N-ethylacetamide: HPLC Retention time; 9.508 min.(Method B) M+1; 479.2

25

30 Compounds listed below were prepared according to the above procedure.

35

Compound Number	Structure	MW	RT, min.	M+1
21-1		522.05	8.648	522.3
21-2		478.981	9.508	479.3
21-3		493.008	9.79	493.2
21-4		478.981	9.472	479.3
21-5		464.954	9.268	465.3
21-6		505.019	9.676	505.2


30

35

Compound Number	Structure	MW	RT, min	M+1
21-7		450.928	7.933	451.0
21-8		521.018	9.644	521.6
21-9		579.957	6.1	507.4


EXAMPLE 22
REDUCTIVE AMINATION

5



10

15



4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl 4-[(methylethyl)amino]piperidyl ketone

hydrochloride







1-[(4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl)carbonyl]piperidin-4-one (400 mg, 0.980 mmol) was dissolved in 10 mL EtOH along with isopropylamine (58 mg, 0.980 mmol). Sodium cyanoborohydride (62 mg, 0.986 mmol) was added and the mixture was stirred at room temperature for 18 hours. The reaction was quenched with water, extracted with ethyl acetate followed by flash chromatography (EtOAc / MeOH ; 90:10) to give a residue. This was taken up in ETOH saturated with HCl(g), diluted with ether, filtered to give 4-{{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}phenyl 4-[(methylethyl)amino]piperidyl ketone hydrochloride (0.150 g, 30 % yield): HPLC Retention time; 6.02 min. (Method B) M+1; 450.4.

30

Compounds listed below were prepared according to the above procedure.

35



Compound Number	Structure	MW	RT, min	M+1
-----------------	-----------	----	---------	-----

5	22-1		522.905	6.02	450.4
10	22-2		490.0478	10.612	490.3
15	22-3		465.9822	9.644	466.3
20	22-4		465.9822	9.604	466.3
25	22-5		465.9822	9.52	466.4
30	22-6		465.9822	9.584	466.4
35					

	22-7		480.009	9.604	480.2
5					
	22-8		519.0895	9.172	519.4
10					
	22-9		517.286	5.89	408.4
15					
	22-10		588.4076	5.43	479.4
20					
	22-11		451.9554	6.12	452.4
25					

30

35

22-12		480.009	9.291	480.4
22-13		447.9674	9.976	448.4

20


25

30


35

EXAMPLE 23
SYNTHESIS OF REVERSE SULFONAMIDES

5



10




15

20



25



30

35

(2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one

A mixture of 4-nitroacetophenone (20.0 g, 121 mmol) and N,N-dimethylformamide dimethylacetal (200 ml) was refluxed for 18 hours, cooled and concentrated to give (2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one quantitatively.

5

1-Acetyl-4-[(4-{{[4-(4-nitrophenyl)pyrimidin-2-yl]amino}phenyl}carbonyl)piperazine

To a mixture of (2E)-1-(4-nitrophenyl)-3-dimethylamino)prop-2-en-1-one (250 mg, 1.14 mmol) and {4-[(4-acetylpirerazinyl)carbonyl]phenyl}aminocarboxamide (394 mg, 1.36 mmol) in methanol (6 ml) is added 2 mL of a 2.0M solution of sodium methoxide in methanol. The reaction mixture is then refluxed for 18 hours then acidified to pH ~ 4 using 1N HCl. The solid which formed at this time was then filtered and purified by column chromatography using 10% methanol in chloroform to give 320 mg (69%) of the desired product.

10

1-Acetyl-4-[(4-{{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl}carbonyl)piperazine

To a solution of 1-acetyl-4-[(4-{{[4-(4-nitrophenyl)pyrimidin-2-yl]amino}phenyl}carbonyl)piperazine (150 mg, 0.34 mmol) in methanol (5mL) containing a few drops of acetic acid, is added 100 mg of 10% Palladium-Charcoal. The solution is then hydrogenated at 50 psi for 6h at which time there remains no starting material. The solution is then filtered through a pad of Celite which gives 135 mg (95%) of essentially pure reduced material as a brown oil.

20

1-Acetyl-4-{{[4-({{4-[(4-phenylsulfonyl)aminophenyl]pyrimidin-2-yl}amino)phenyl}carbonyl)piperazine









25









To a solution of 1-acetyl-4-[(4-{{[4-(4-aminophenyl)pyrimidin-2-yl]amino}phenyl}carbonyl)piperazine (100 mg, 0.24 mmol) in pyridine (5 mL) containing a catalytic amount of DMAP is added benzenesulfonyl chloride (50 mg, 0.29 mmol) and the solution is stirred overnight at room temperature. The pyridine is removed under vacuum and the residue extracted into methylene chloride and washed with 1N HCl. Evaporation of solvent provides the crude piperazine which is purified by preparative HPLC (10-60% CH₃CN over 25 min.) to give an analytically pure sample as a yellow solid: M+1; 557.3. HPLC Retention Time; 9.59 min (Method B).

30
35

Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
23-1		586	8.03	587.3
23-2		624.6413	9.53	625.3
23-3		570.671	8.46	571.3


5	23-4		586.67	9	587.5
10	23-5		556.644	9.62	557.3
15	23-6		494.5734	8.35	495.3
20	23-7		591.0893	10.14	591.3
25	23-8		598.7246	10.25	599.5
30	23-9		624.6413	10.58	625.3
35	23-10		562.6724	9.56	563.3
	23-11		570.671	10.02	571.3

23-12		570.671	9.79	571.3	
5	23-13		601.6413	7.15	602.5
10	23-14		601.6413	8.57	602.3
15	23-15		614.7236	8.23	615.5
20	23-16		514.6074	4.55	515.3
25	23-17		523.6151	8.85	524.3
30	23-18		586.67	9.72	587.3
35	23-19		570.671	9.82	571.3

23-20	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)S(=O)(=O)c8ccccc8)C2=O</chem>	570.671	10.68	571.5
5 23-21	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)C(=O)N8CCCC[C@H]8C(=O)C2=O)C</chem>	520.5902	9.89	521.3
10 23-22	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)C(=O)N8CCCC[C@H]8C(=O)C2=O)C</chem>	535.6051	7.58	536.3
15 23-23	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)S(=O)(=O)c8ccccc8)C2=O</chem>	582.682	9.18	583.5
20 23-24	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)C(=O)N8CCCC[C@H]8C(=O)C2=O)C</chem>	596.7088	9.76	597.5
25 23-25	<chem>CN1CC[C@H]2[C@H]1C(=O)N3[C@H](C[C@H]3C(=O)c4ccc(cc4)-c5nc6ccccc6[nH]5)N(c7ccc(cc7)C(=O)N8C(C)=C9C(=O)ON=C9C(=O)C8=O)C</chem>	637.7179	9.8	638.3

30

35

23-26		623.6911	9.2	624.5
23-27		528.6342	5.92	529.3


10

15


EXAMPLE 24

SYNTHESIS OF FURTHER REPRESENTATIVE COMPOUNDS

20



25



30





The compounds of Example 18, with the desired R₁ moiety, may be modified according to the above procedures to yield further representative compounds of this invention. For example, the following compounds were made according to the above procedures.





35

Compound Number	Structure	MW	RT, min	M+1
24-1		498.963	9.7	499
24-2		471.967	7.19	472
24-3		512.990	6.24	513
24-4		478.974	5.92	479

30

35





Compound Number	Structure	MW	RT, min	M+1
24-5		497.975	7.41	498
24-6		526.037	7.66	526
24-7		512.9985	8.350	513.4
24-8		478.9813	7.533	479.4





Compound Number	Structure	MW	RT, min	M+1
24-9		552.028	7.33	552.3
24-10		559.048	7.17	559.3
24-11		585.92	5.15	513.3
24-12		585.92	4.78	513

Compound Number	Structure	MW	RT, min	M+1
24-13		516.987	6.43	517.3
24-14		477.993	6.95	478.3
24-15		489.883	7.12	490.3
24-16		504.012	6.77	504.3

Compound Number	Structure	MW	RT, min	M+1
24-17		490.004	7.2	504.3
24-18		475.977	6.58	476.3
24-19		476.938	5.55	479.3
24-20		533.073	4.63	533.3

Compound Number	Structure	MW	RT, min	M+1
24-21		506.991	1.1	507.3
24-22		507.035	4.61	508.3
24-23		465.939	5.99	466.3
24-24		461.951	6.41	462.3






Compound Number	Structure	MW	RT, min	M+1
24-25		482.006	6.57	496.3
24-26		492.02	7.14	492.3
24-27		503.91	6.69	504.3
24-28		548.043	7.27	548.3

Compound Number	Structure	MW	RT, min	M+1
24-29		565.93	5.99	493.4
24-30		476.966	7.16	477.4
24-31		648.993	8.56	649.4
24-32		449.94	6.92	450.4

30

35


Compound Number	Structure	MW	RT, min	M+1
24-33		464.954	6.09	465.3
24-34		519.046	6.87	519.3
24-35		522.99	7.19	524.4
24-36		537.017	4.52	537.4
24-37		537.021	7.79	537.2

Compound Number	Structure	MW	RT, min	M+1
24-38		504.975	6.72	505.4
24-39		486.961	6.92	487.4
24-40		487.949	6.08	488.4
24-41		486.961	7.27	487.4
24-42		502.96	7.27	503.4


Compound Number	Structure	MW	RT, min	M+1
5 24-43		502.9597	7.27	503.4
10 24-44		533.0535	7.19	533.2
15 24-45		488.9329	7.09	489.4
20 24-46		588.4076	3.25	478.3
25 24-47		515.0143	7.16	515.4

EXAMPLE 25
SYNTHESIS OF SULFIDES

5




10



15

20



25

30

3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone

To a stirred solution of 4-hydroxybutanethiol (5.0 g, 47 mmol) in DMF (100 mL) was added NaH (60% dispersion in mineral oil, 2.1 g). After the effervescence had ceased, *p*-chloroacetophenone (4.3 mL, 33 mmol) was added. The solution was then stirred at 110 °C for 3 h. The mixture was cooled to RT and then diluted with ether (200 mL). The ethereal

35

suspension was washed with 5% HCl (aq, 2 x 100 mL), water (100 mL), and then brine (50 mL). The ether extract was dried (MgSO_4), filtered and concentrated to afford crude 1-[4-(4-hydroxybutylsulfanyl)phenyl]ethanone, which was used without purification. 1-[4-(4-hydroxybutylsulfanyl)phenyl]ethanone was taken up in dimethylformamide dimethylacetal (100 mL) and stirred at reflux for 12h. The mixture was cooled and then concentrated to about one half of the original volume. Hexane was added to precipitate 3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone. The mixture was filtered, washed with hexanes (50 mL), and dried to afford 3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)phenyl]propenone (6.4g, 23 mmol): HPLC Retention Time; 5.58 min. (Method B) M+1; 279.8.

10

4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic Acid

3-Dimethylamino-1-[4-(4-hydroxybutylsulfanyl)-phenyl]propenone (6.4g, 23 mmol) was, then taken up in *n*PrOH (150 mL). To this solution was added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 5.4 g) and K_2CO_3 (3 equiv, 9.5 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted to pH 4.5 to 4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic acid. The acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (8.6 g, 21 mmol, 88%): HPLC Retention Time; 6.37 min. (Method B) M+1; 396.0.

15





20

[4-(Furan-2-carbonyl)piperazin-1-yl]-[4-{4-[4-(4-hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}phenyl]methanone

4-{4-[4-(4-Hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}benzoic acid (0.34 g, 0.86 mmol) was dissolved in THF (5 mL). To this solution was added 1-furoylpiperazine (0.170 g), EDCI (0.180 g), and HOBr (0.127 g). The mixture was stirred 12h. The mixture was then diluted with CH_2Cl_2 (20 mL) and washed with 2% NaOH (aq, 30 mL), water (30 mL), and then brine (30 mL). The organic layer was dried (Na_2SO_4), filtered, and concentrated. The crude solid was subjected to preparatory HPLC (30 – 80 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with CH_2Cl_2 /2% NaOH (aq). The organic layer was dried (Na_2SO_4), filtered, and concentrated to afford [4-(Furan-2-carbonyl)-piperazin-1-yl]-[4-{4-[4-(4-hydroxybutylsulfanyl)phenyl]pyrimidin-2-ylamino}phenyl]methanone (0.042 g, 9%): HPLC Retention Time; 10.07 min. (Method B) M + H = 558.3.

35

Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
5 25-1		557.672	10.07	558.3
10 25-2		505.64	9.26	506.3
15 25-3		562.735	8.81	563.3
20 25-4		500.064	8.37	464.4
25 30				





5	25-5	<p><chem>O=C1CCOCOCSCc2ccc(cc2)-c3ccnc4ncn3c4C(=O)N1CC2CCCCS2</chem></p>	571.699	12.04	572.3
10	25-6	<p><chem>CN(C)C(=O)N1CCOCOCSCc2ccc(cc2)-c3ccnc4ncn3c4C1=O</chem></p>	519.667	11.13	520.3
15	25-7	<p><chem>CC(C)N(C)C(=O)N1CCOCOCSCc2ccc(cc2)-c3ccnc4ncn3c4C1=O</chem></p>	576.762	10.24	577.2
20	25-8	<p><chem>CN1CCOCOCSCc2ccc(cc2)-c3ccnc4ncn3c4C(=O)N1C(Cl)H</chem></p>	514.091	9.7	478.3
25	25-9	<p><chem>O=C1CCOCOCSCc2ccc(cc2)-c3ccnc4ncn3c4C(=O)N1CCCOCCS</chem></p>	529.618	9.5	530.3
30					
35					

25-10	<chem>CC(=O)N1CCCN(C(=O)c2ccc3c(c2)nc4ccncn4)C1Cc5ccc(cc5)S(=O)(=O)CO</chem>	477.586	8.66	478.2
25-11	<chem>CC(C)N(C)C(=O)CN1CCCN(C(=O)c2ccc3c(c2)nc4ccncn4)C1Cc5ccc(cc5)S(=O)(=O)CO</chem>	534.682	7.32	535.3
25-12	<chem>CN1CCCN(C(=O)c2ccc3c(c2)nc4ccncn4)C1Cc5ccc(cc5)S(=O)(=O)CO</chem> CIH	472.01	6.88	436.2





25





30

35


25-13		571.699	10.62	572.3
25-14		519.667	9.76	520.2
25-15		477.63	8.77	478.3
25-16		491.657	8.9	492.3

25-17		576.762	9.25	577.3
5				
10		492.641	9.59	493.3
15				
20		562.779	8.42	563.3
25				
30		588.773	8.51	589.3
35				

25-21		571.699	10.85	572.3
25-22		519.667	10.05	520.3
25-23		477.63	9	478.3
25-24		576.762	9.46	577.3

5	25-25		491.657	9.1	492.3
10	25-26		562.779	8.58	563.3
15	25-27		588.773	9.39	589.5
20	25-28		492.641	9.84	493.3

EXAMPLE 26



30 1-[4-(Morpholine-4-sulfonyl)phenyl]ethanone

To a suspension of 4-acetylbenzenesulfonyl chloride (5.5 g, 25 mmol) in CH_2Cl_2 (75 mL) and Et_3N (2 equiv, 7.0 mL, 50 mmol) was added morpholine (1.5 equiv, 3.3 mL, 38 mmol) dropwise. The mixture was stirred at room temperature for 30 min. The mixture was then diluted with CH_2Cl_2 (100 mL) and washed with 5% HCl (2 x 50 mL), water (50 mL), and then brine (50 mL). The organic layer was dried (Na_2SO_4), filtered, and concentrated to afford

crude 1-[4-(morpholine-4-sulfonyl)phenyl]ethanone (2) (4.78g, 18 mmol, 71%): HPLC Retention Time; 5.82 min. (Method B) M+1, 270.0.

4-{4-[4-(Morpholine-4-sulfonyl)-phenyl]-pyrimidin-2-ylamino}benzoic Acid




5 Crude 1-[4-(morpholine-4-sulfonyl)phenyl]ethanone (4.78g, 18 mmol) was suspended in dimethylformamide dimethylacetal (50 mL) and refluxed for 12 h. The reaction was allowed to cool and the mixture was concentrated to about half of the original volume. The solution was then titrated with hexanes to precipitate the eneamino ketone intermediate. The eneamino ketone was filtered and washed with hexanes (2 x 50 mL), dried under vacuum, and
10 then taken up in *n*PrOH (150 mL). To this solution was added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 3.7 g) and K₂CO₃ (3 equiv, 6.4 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted to pH 4-5 to
15 precipitate the acid. 4-{4-[4-(morpholine-4-sulfonyl)phenyl]pyrimidin-2-ylamino}benzoic acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (4.6 g, 10.5 mmol, 68%): HPLC Retention Time; 6.6 min. (Method B) M+1, 441.0.





[4-(Furan-2-carbonyl)-piperazin-1-yl](4-{4-[4-(morpholine-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone





20 4-{4-[4-(Morpholine-4-sulfonyl)-phenyl]-pyrimidin-2-ylamino}-benzoic acid (0.25 g, 0.57 mmol) was dissolved in THF (5 mL). To this solution was added 1-furoylpiperazine (0.123 g), EDCI (0.131 g), and HOBr (0.092 g). The mixture was stirred 12h. The mixture was then diluted with CH₂Cl₂ (20 mL) and washed with 2% NaOH (aq, 30 mL),
25 water (30 mL), and then brine (30 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated. The crude solid was subjected to preparatory HPLC (20 – 70 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with CH₂Cl₂/2% NaOH (aq). The organic layer was dried (Na₂SO₄), filtered, and concentrated to afford [4-(furan-2-carbonyl)piperazin-1-yl](4-{4-[4-(morpholine-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}phenyl)methanone (0.177 g, 52%):
30 HPLC Retention Time; 9.62 min. (Method B)





M + H = 603.3

Compounds listed below were prepared according to the above procedure.





Compound Number	Structure	MW	RT, min	M+1
5 26-1		602.669	9.62	603.3
10 26-2		550.637	8.88	551.3
15 26-3		508.6	7.6	509.3





5	26-4		607.732	8.34	608.3
10	26-5		522.627	7.9	523.3
15	26-6		593.749	6.33	594.3
20	26-7		619.743	8.28	620.3
25					
30					





5	26-8		523.611	8.76	524.3
10	26-9		576.718	8.21	577.3
15	26-10		576.675	10.26	577.3
20	26-11		592.717	12.12	593.3
25					
30					





26-12		564.664	10.04	565.3
26-13		578.691	10.51	579.3
26-14		631.711	10.33	632.4
26-15		466.563	10.4	467.3





5	26-16		508.6	11.35	509.3
10	26-17		560.632	12	561.3
15	26-18		616.696	9.72	617.3
20	26-19		564.664	8.93	565.5
25					
30					

5	26-20		522.627	7.99	523.3
10	26-21		590.745	8.34	591.3
15	26-22		563.6797	8.05	564.3
20	26-23		591.6897	9.01	592.3
30					

26-24		619.7433	9.25	620.3
26-25		548.6648	10.88	549.5
26-26		534.638	10	535.3
26-27		552.6528	6.82	553.3





26-28		522.627	10.18	523.3
26-29		617.7711	8.31	618.5
26-30		556.6442	10.29	557.2
26-31		494.5734	8.96	495.3






5	26-32		562.6916	11.36	563.4
10	26-33		562.6916	11.2	563.4
15	26-34		562.6916	11.52	563.4
20	26-35		562.6916	11.5	563.4






5	26-36		564.6638	9.14	565.4
10	26-37		549.6529	8.04	550.4
15	26-38		565.6519	8.26	566.3
20	26-39		538.626	9.14	539.3





30







35








26-40		551.6687	7.77	552.3
26-41		506.628	9.64	507.4
26-42		492.6012	9.08	493.4
26-43		534.6816	9.9	535.3

5	26-44		591.7769	9.16	592.5
10	26-45		578.7342	10.25	579.5
15	26-46		520.6548	9.32	521.5
20	26-47		564.7074	9.7	565.5
25	26-48		577.7501	8.66	578.5




5	26-49		563.7233	8.77	564.5
10	26-50		577.7501	9.28	578.5
15	26-51		536.6538	8.89	537.5
20	26-52		580.7064	9.29	581.4
25	26-53		579.7223	8.4	580.5
30					
35					

5	26-54		538.6629	9.44	539.3
10	26-55		494.617	9.06	495.3
15	26-56		537.6855	8.56	538.5
20	26-57		551.7123	8.47	552.5
25					
30					

	26-58		536.6538	10.64	537
5	26-59		570.671	10.63	571
10	26-60		576.7184	11.43	577
15	26-61		596.7054	10.01	597
20	26-62		550.6806	11.75	551
25	26-63		564.7074	11.82	565
30					

5	26-64		571.6591	8.11	572
10	26-65		536.6538	10.28	537
15	26-66		536.6538	10.24	537
20	26-67		579.6787	8.71	580
25	26-68		591.0893	11.07	591
30	26-69		562.6916	10.9	563
	26-70		560.6322	10.74	561

EXAMPLE 27
SYNTHESIS OF SULFONES



To a stirred solution of Na_2S (17.4 g, 0.22 mol) in water (26 mL) was added CS_2 (14.7 mL, 0.24 mol). The mixture was stirred at 60 – 70°C for 6h. To the resultant red solution of Na_2CS_3 was added 4-chlorotetrahydropyran (0.074 mol). The mixture was stirred for 12h at 60 – 70°C. The mixture was then cooled to ~10°C. H_2SO_4 (conc.) was

added to the mixture dropwise with stirring until a cloudy yellow color persisted. The mixture was then extracted with CH_2Cl_2 (3 x 50 mL). The aqueous layer was discarded and the CH_2Cl_2 layer was dried (Na_2SO_4), filtered, and concentrated. The crude thiol (47.5 mmol, ~64%) was dissolved in DMF (100 mL) and treated with NaH (1.9g, 48 mmol).

- 5 After the effervescence had ceased, *p*-chloroacetophenone (4.3 mL, 33 mmol) was added. The solution was then stirred at 110°C for 3 h. The mixture was cooled to RT and then diluted with ether (200 mL). The ethereal suspension was washed with 5% HCl (aq, 2 x 100 mL), water (100 mL), and then brine (50 mL). The ether extract was dried (MgSO_4), filtered and concentrated to afford crude 1-[4-(tetrahydro-pyran-4-sulfanyl)-phenyl]-ethanone 1, which was purified by chromatography (SiO_2 , 9:1 hex/EtOAc) to afford pure 1-[4-(tetrahydropyran-4-sulfanyl)phenyl]ethanone 1 (7.4 mmol, 16% from 4-chlorotetrahydropyran): HPLC Retention Time; 5.41 min. (Method B) M+1; 269.0.

3-Dimethylamino-1-[4-(tetrahydropyran-4-sulfonyl)phenyl]propanone

- 15 1-[4-(Tetrahydro-pyran-4-sulfanyl)-phenyl]-ethanone 1 (7.4 mmol) was dissolved in acetone/water (9:1 v/v, 100 mL). Oxone® (2.1 equiv, 9.1 g) was added to the solution. The reaction was stirred at room temperature for 5h. The mixture was filtered and the majority of acetone was removed *in vacuo*. The solution was then diluted with water (50 mL) and extracted with CH_2Cl_2 (3 x 50 mL). The organic layer was dried (Na_2SO_4), filtered, and concentrated to afford the intermediate tetrahydropyranyl sulfone, which was taken up in dimethylformamide dimethylacetal (100 mL) and stirred at reflux for 12h. The mixture was cooled and then concentrated to about one half of the original volume. Hexane was added to precipitate eneamino ketone intermediate. The mixture was filtered, washed with hexanes (50 mL), and dried to afford 3-dimethylamino-1-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-propanone (2.2g, 7 mmol): HPLC Retention Time; 5.18 min. (Method B) M+1; 324.0.

4-{4-[4-(Tetrahydropyran-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}benzoic Acid

- 30 3-Dimethylamino-1-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-propanone was then taken up in *n*PrOH (80 mL). To this solution was added 4-guanidinobenzoic acid, methyl ester, hydrochloride salt (1.1 equiv, 1.7 g) and K_2CO_3 (3 equiv, 2.9 g). The mixture was stirred at reflux for 24 h. After this time, 10% NaOH (aq, 50 mL) was added, and the mixture was stirred at reflux for another 1 h. The mixture was then cooled to RT and concentrated to about half of the original volume. The pH of the mixture was then adjusted to pH 4-5 to precipitate 4-{4-[4-(tetrahydro-pyran-4-sulfonyl)-phenyl]-pyrimidin-2-





ylamino}-benzoic acid 4. The acid was immediately filtered and washed with water (50 mL), cold EtOH (50 mL), and then dried (2.4 g, 5.5 mmol, 79% yield): HPLC Retention Time; 6.07 min. (Method B) M+1; 593.3.





5 [4-(3-Dimethylamino-propyl)-piperazin-1-yl]-[4-{4-[4-(tetrahydropyran-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone




4-{4-[4-(Tetrahydropyran-4-sulfonyl)-phenyl]pyrimidin-2-ylamino}benzoic acid 4 (0.26 g, 0.6 mmol) was dissolved in THF (5 mL). To this solution was added 1-(N,N-dimethylaminopropyl)piperazine (0.130 g), EDCI (0.136 g), and HOBr (0.096 g). The mixture was stirred 12h. The mixture was then diluted with CH₂Cl₂ (20 mL) and washed with 2% NaOH (aq, 30 mL), water (30 mL), and then brine (30 mL). The organic layer was dried (Na₂SO₄), filtered, and concentrated. The crude solid was subjected to preparative HPLC (20 – 70 acetonitrile/water gradient, 20 min). The desired fractions were concentrated to remove most of the acetonitrile, and then the aqueous mixture was extracted with CH₂Cl₂/2% NaOH (aq). The organic layer was dried (Na₂SO₄), filtered, and concentrated to afford [4-(3-dimethylamino-propyl)piperazin-1-yl]-[4-{4-[4-(tetrahydropyran-4-sulfonyl)phenyl]pyrimidin-2-ylamino}phenyl)methanone 5 (0.079 g, 22%): HPLC Retention Time; 7.93 min. (Method B) M + 1 = 593.3

20 Compounds listed below were prepared according to the above procedure.

Compound Number	Structure	MW	RT, min	M+1
27-1		612.664	10.25	595.3





27-2		542.617	8.7	543.3
27-3		515.591	8.57	516.3
27-4		623.6911	9.36	624.3
27-4		601.681	10.06	602.4





27-5		606.744	8.64	607.4
5				
27-6		507.612	8.37	508.3
10				
27-7		521.639	8.57	522.3
15				
27-8		592.761	7.93	593.3
20				
25				
30				

27-9		575.73	8.57	576.3
27-10		522.623	8.95	523.3
27-11		630.723	10.25	631.3

30

35

27-12		549.649	9.5	550
27-13		500.5806	8.8	501.3
27-14		571.699	9.78	572.3
27-15		583.71	9.736	584.5

27-16		541.629	10.484	542.3
27-17		593.661	11.264	594.3
27-18		513.619	9.336	514.3
27-19		572.514 ClH CH	9.204	500

5	27-20		584.741	8.692	585.2
10	27-21		528.63	10.648	529.2
15	27-22		458.54	11.44	458.9
25					

EXAMPLE 28ASSAYS FOR MEASURING ACTIVITY OF COMPOUNDS

30 The compounds of this invention may be assayed for their activity according to the following procedures.

JNK2 Assay

35 To 10 μ L of the test compound in 20% DMSO/80% dilution buffer consisting of 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 2.5 mM magnesium chloride,

0.004% Triton x100, 2 µg/mL leupeptin, 20 mM β -glycerolphosphate, 0.1 mM sodium vanadate, and 2 mM DTT in water is added 30 µL of 50 ng His6-JNK2 in the same dilution buffer. The mixture is preincubated for 30 minutes at room temperature. Sixty microliter of 10 µg GST-c-Jun(1-79) in assay buffer consisting of 20 mM HEPES (pH 7.6), 50 mM sodium chloride, 0.1 mM EDTA, 24 mM magnesium chloride, 1 mM DTT, 25 mM PNPP, 0.05% Triton x100, 11 µM ATP, and 0.5 µCi γ -³²P ATP in water is added and the reaction is allowed to proceed for 1 hour at room temperature. The c-Jun phosphorylation is terminated by addition of 150 µL of 12.5% trichloroacetic acid. After 30 minutes, the precipitate is harvested onto a filter plate, diluted with 50 µL of the scintillation fluid and quantified by a counter. The IC₅₀ values are calculated as the concentration of the test compound at which the c-Jun phosphorylation is reduced to 50% of the control value. Preferred compounds of the present invention have an IC₅₀ value ranging 0.01 - 10 µM in this assay.

15 JNK3 Assay

To 10 µL of the test compound in 20% DMSO/80% dilution buffer consisting of 20 mM HEPES (pH 7.6), 0.1 mM EDTA, 2.5 mM magnesium chloride, 0.004% Triton x100, 2 µg/mL leupeptin, 20 mM β -glycerolphosphate, 0.1 mM sodium vanadate, and 2 mM DTT in water is added 30 µL of 200 ng His6-JNK3 in the same dilution buffer. The mixture is preincubated for 30 minutes at room temperature. Sixty microliter of 10 µg GST-c-Jun(1-79) in assay buffer consisting of 20 mM HEPES (pH 7.6), 50 mM sodium chloride, 0.1 mM EDTA, 24 mM magnesium chloride, 1 mM DTT, 25 mM PNPP, 0.05% Triton x100, 11 µM ATP, and 0.5 µCi γ -³²P ATP in water is added and the reaction is allowed to proceed for 1 hour at room temperature. The c-Jun phosphorylation is terminated by addition of 150 µL of 12.5% trichloroacetic acid. After 30 minutes, the precipitate is harvested onto a filter plate, diluted with 50 µL of the scintillation fluid and quantified by a counter. The IC₅₀ values are calculated as the concentration of the test compound at which the c-Jun phosphorylation is reduced to 50% of the control value. Preferred compounds of the present invention have an IC₅₀ value ranging 0.01 - 10 µM in this assay.

Jurkat T-cell IL-2 Production Assay

Jurkat T cells (clone E6-1) are purchased from the American Tissue Culture Collection and maintained in growth media consisting of RPMI 1640 medium containing 2 mM L-glutamine (Mediatech), with 10% fetal bovine serum (Hyclone) and

penicillin/streptomycin. All cells are cultured at 37°C in 95% air and 5% CO₂. Cells are plated at a density of 0.2 x 10⁶ cells per well in 200 µL of media. Compound stock (20 mM) is diluted in growth media and added to each well as a 10x concentrated solution in a volume of 25 µL, mixed, and allowed to pre-incubate with cells for 30 minutes. The compound
5 vehicle (dimethylsulfoxide) is maintained at a final concentration of 0.5% in all samples. After 30 minutes the cells are activated with PMA (phorbol myristate acetate; final concentration 50 ng/mL) and PHA (phytohemagglutinin; final concentration 2 µg/mL). PMA and PHA are added as a 10x concentrated solution made up in growth media and added in a volume of 25 µL per well. Cell plates are cultured for 10 hours. Cells are pelleted by
10 centrifugation and the media removed and stored at -20 °C. Media aliquots are analyzed by sandwich ELISA for the presence of IL-2 as per the manufacturers instructions (Endogen). The IC₅₀ values are calculated as the concentration of the test compound at which the IL-2 production was reduced to 50% of the control value. Preferred compounds of the present invention have an IC₅₀ value ranging 0.1 - 30 µM in this assay.

15

Rat *in vivo* LPS-induced TNF-α Production Assay

Male CD rats procured from Charles River Laboratories at 7 weeks of age are allowed to acclimate for one week prior to use. A lateral tail vein is cannulated percutaneously with a 22-gage over-the-needle catheter under brief isoflurane anesthesia.
20 Rats are administered test compound either by intravenous injection via the tail vein catheter or oral gavage 15 to 180 min prior to injection of 0.05 mg/kg LPS (E. Coli 055:B5). Catheters are flushed with 2.5 mL/kg of normal injectable saline. Blood is collected via cardiac puncture 90 minutes after LPS challenge. Plasma is prepared using lithium heparin separation tubes and frozen at -80°C until analyzed. TNF-α levels are determined using a rat
25 specific TNF-α ELISA kit (Busywork). The ED₅₀ values are calculated as the dose of the test compound at which the TNF-α production is reduced to 50% of the control value. Preferred compounds of the present invention have an ED₅₀ value ranging 1-30 mg/kg in this assay.

Detection of Phosphorylated c-Jun

30 Human umbilical vein endothelial cells (HUVEC) are cultured to 80% confluence and then pre-treated with compound (30 µM) at a final concentration of 0.5% DMSO. After 30 minutes, cells are stimulated with TNFα (30 ng/ml) for 20 minutes. Cells are washed, scraped from the plate, lysed with 2x Laemmli buffer and heated to 100°C for 5 minutes. Whole cell lysate (approx. 30 µg) is fractionated on Tris-glycine buffered 10%
35 SDS-polyacrylamide gels (Novex, San Diego, CA) and transferred to nitrocellulose

membrane (Amersham, Piscataway, NJ). Membranes are blocked with 5% non-fat milk powder (BioRad, Hercules, CA) and incubated with antibody to phospho-cJun (1:1000 #91645) (New England Biolabs, Beverly, MA) and then donkey anti-rabbit horse radish peroxidase conjugated antibody (1:2500) (Amersham) in phosphate buffered saline with 5 0.1% Tween-20 and 5% non-fat milk powder. Immunoreactive proteins are detected with chemiluminescence and autoradiography (Amersham). Compounds are selected as inhibitors of the JNK pathway if they showed greater than 50% inhibition of cJun phosphorylation at 30 μ m in this assay.

10

EXAMPLE 29ACTIVITY OF REPRESENTATIVE COMPOUNDS


Representative compounds of this invention were assayed for their ability to inhibit JNK2 by the assay set forth in Example 28. As noted above, preferred compounds of 15 this invention have an IC₅₀ value ranging 0.01 - 10 μ M in this assay. To this end, compounds having an IC₅₀ value in the JNK2 Assay of 10 μ M or less include Compound Nos. 1, 3-2, 3-4, 3-9, 3-10, 3-11, 3-12, 3-13, 3-14, 3-15, 3-16, 3-17, 3-22, 3-23, 3-24, 3-25, 3-26, 3-27, 3-29, 3-30, 3-34, 3-36, 3-37, 3-40, 17-2, 17-3, 17-6, 17-18, 17-20, 17-21, 17-22, 17-23, 17-24, 17-25, 17-26, 17-27, 17-28, 17-29, 17-30, 17-31, 17-32, 17-33, 17-34, 17-35, 17-37, 20 17-54, 17-86, 17-91, 17-106, 17-118, 17-119, 17-121, 17-127, 17-128, 17-129, 17-130, 17-131, 17-132, 17-133, 17-134, 17-135, 17-136, 17-137, 17-139, 17-140, 17-141, 17-142, 17-143, 17-144, 17-147, 17-148, 17-149, 17-150, 17-151, 17-152, 17-153, 17-154, 17-157, 17-158, 17-159, 17-160, 17-161, 17-162, 17-163, 17-164, 17-169, 17-171, 17-190, 17-215, 18, 25 20-1, 20-2, 20-3, 20-4, 20-5, 20-6, 22-10, 22-11 and 25-52. Preferred compounds of this invention have an IC₅₀ value in the JNK2 assay of 1 μ M or less, and include Compound Nos. 3-2, 3-4, 3-9, 3-13, 3-14, 3-15, 3-23, 3-24, 3-25, 3-40, 17-20, 17-21, 17-22, 17-24, 17-29, 17-30, 17-31, 17-32, 17-33, 17-34, 17-37, 17-127, 17-129, 17-137, 17-141, 17-147, 17-154, 17-169, 17-171, 17-190, 18, 20-1, 20-3, 20-4, 22-10, 22-11, and 25-52.

30

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall 35 within the appended claims.

What is claimed is:

1. A method for treating a condition responsive to inhibition of the JNK pathway, comprising administering to a patient in need thereof and effective amount of a compound having the structure:



10

or a pharmaceutically acceptable salt thereof,

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R₇;

15

R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

R₄ represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

20

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉, -(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀, -(CH₂)_aNR₉(CH₂)_bC(=O)R₁₀, -(CH₂)_aNR₉C(=O)R₁₀, -(CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉R₁₀, -(CH₂)_aOR₉, -(CH₂)_aSO_cR₉, or -(CH₂)_aSO₂NR₉R₁₀;

25

or R₅ and R₆ taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

35

R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence

independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocycloalkyl or substituted heterocycloalkyl;

or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.

10 2. The method of claim 1 wherein the condition is an inflammatory or autoimmune condition.

15 3. The method of claim 2 wherein the inflammatory or autoimmune condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus.

20 4. The method of claim 1 wherein the condition is a cardiovascular, metabolic or ischemic condition.

25 5. The method of claim 4 wherein the condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, Type II diabetes, osteoporosis, erectile dysfunction, cachexia, myocardial infarction, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, or multiple organ failure.

30 6. The method of claim 1 wherein the condition is an infectious disease.

7. The method of claim 6 wherein the infectious disease is a viral infection.

35 8. The method of claim 7 wherein the viral infection is caused by human

immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papilomavirus, human T-cell leukemia virus or Epstein-Barr virus.

9. The method of claim 1 wherein the condition is cancer.

5

10. The method of claim 9 wherein the cancer is of the colon, rectum, prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, testes, urinary bladder, ovary or uterus.

10


11. The method of claim 1 wherein the condition is stroke, epilepsy, Alzheimer's disease or Parkinson's disease.

12. The method of claim 9 further comprising administering an effective amount of a cytotoxic agent or radiation therapy.

15

13. A method for treating an inflammatory or an autoimmune condition comprising administering to a patient in need thereof an effective amount of a compound having the structure:

20



or a pharmaceutically acceptable salt thereof,

25

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R₇;

R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

30

R₄ represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉, -(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀, -(CH₂)_aNR₉C(=O)R₁₀,

35

$-(CH_2)_\alpha NR_{11}C(=O)NR_9R_{10}$, $-(CH_2)_\alpha NR_9R_{10}$, $-(CH_2)_\alpha OR_9$,
 $-(CH_2)_\alpha SO_cR_9$, or $-(CH_2)_\alpha SO_2NR_9R_{10}$;

or R_5 and R_6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

5 R_7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_cR_8$, $-SO_cNR_8R_9$, $-NR_8SO_cR_9$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

10 R_8 , R_9 , R_{10} and R_{11} are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

15 or R_8 and R_9 taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

20 a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.

14. The method of claim 13 further comprising administering an effective amount of an anti-inflammatory agent.


25

15. The method of claim 14, wherein the anti-inflammatory agent is salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbiprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, piroxicam, tenoxicam, nabumetone, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide, zileuton, aurothioglucose, gold sodium thiomalate, auranofin, colchicine, allopurinol, probenecid, sulfinpyrazone, benz bromarone, enbrel, infliximab, anakinra, celecoxib or rofecoxib.

35

16. The method of claim 13, wherein the inflammatory or autoimmune condition is rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gout, asthma, bronchitis, allergic rhinitis, chronic obstructive pulmonary disease, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, mucous colitis, ulcerative colitis, 5 Crohn's disease, gastritis, esophagitis, hepatitis, pancreatitis, nephritis, psoriasis, eczema, dermatitis, multiple sclerosis, Lou Gehrig's disease, sepsis, conjunctivitis, acute respiratory distress syndrome, purpura, nasal polip or lupus erythematosus.

17. A method for treating a cardiovascular, metabolic or ischemic 10 condition comprising administering to a patient in need thereof an effective amount of a compound having the structure:



15

or a pharmaceutically acceptable salt thereof,

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents 20 independently selected from R₇;

R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

R₄ represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, 25 hydroxy, lower alkyl or lower alkoxy;

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉, -(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀, 30 -(CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉C(=O)R₁₀, -(CH₂)_aOR₉, -(CH₂)_aSO_cR₉, or -(CH₂)_aSO₂NR₉R₁₀;

or R₅ and R₆ taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, 35 sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted

aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

5 R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

10 or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and


c is at each occurrence 0, 1 or 2.

15

18. The method of claim 17, wherein the condition is atherosclerosis, restenosis following angioplasty, left ventricular hypertrophy, Type II diabetes, osteoporosis, erectile dysfunction, cachexia, myocardial infarction, ischemic diseases of heart, kidney, liver, and brain, organ transplant rejection, graft versus host disease, endotoxin shock, or multiple 20 organ failure.

19. A method for treating an infectious disease comprising administering to a patient in need thereof an effective amount of a compound having the structure:

25



or a pharmaceutically acceptable salt thereof,

30

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R₇;

R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

35 R₄ represents one to four optional substituents, wherein each substituent is

the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉,

- (CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀,

5 - (CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉R₁₀, -(CH₂)_aOR₉,

-(CH₂)_aSO_cR₉, or -(CH₂)_aSO₂NR₉R₁₀;

or R₅ and R₆ taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

10 R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

15 R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

20 or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

25 a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and


c is at each occurrence 0, 1 or 2.

30 20. The method of claim 19 wherein the infectious disease is a viral infection.

35 21. The method of claim 20 wherein the viral infection is caused by human immunodeficiency virus, hepatitis B virus, hepatitis C virus, human papilomavirus, human T-cell leukemia virus or Epstein-Barr virus.

22. A method for treating cancer comprising administering to a patient in

need thereof an effective amount of a compound having the structure:



5

or a pharmaceutically acceptable salt thereof,

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents
10 independently selected from R₇;

R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

R₄ represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉,
-(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉R₁₀,
-(CH₂)_aNR₉(CH₂)_bC(=O)R₁₀, -(CH₂)_aNR₉C(=O)R₁₀,
-(CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉R₁₀, -(CH₂)_aOR₉,
- (CH₂)_aSO_cR₉, or -(CH₂)_aSO₂NR₉R₁₀;

20 or R₅ and R₆ taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, 25 sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, 30 -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

35 or R₈ and R₉ taken together with the atom or atoms to which they are

attached to form a heterocycle or substituted heterocycle;
a and *b* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and
c is at each occurrence 0, 1 or 2.


5

23. The method of claim 22 further comprising administering an effective amount of an anti-cancer agent.

24. The method of claim 23 wherein the anti-cancer agent is
10 cyclophosphamide, Ifosfamide, trofosfamide, Chlorambucil, carmustine (BCNU), Lomustine (CCNU), busulfan, Treosulfan, Dacarbazine, Cisplatin, carboplatin, vincristine, Vinblastine, Vindesine, Vinorelbine, paclitaxel, Docetaxol, etoposide, Teniposide, Topotecan, 9-aminocamptothecin, camptothecin, crisnatol, mytomycin C, methotrexate, Trimetrexate, mycophenolic acid, Tiazofurin, Ribavirin, EICAR, hydroxyurea, deferoxamine, 5-fluorouracil, Flouxuridine, Doxifluridine, Ratitrexed, cytarabine (ara C), cytosine arabinoside, fludarabine, mercaptopurine, thioguanine, Tamoxifen, Raloxifene, megestrol, goscrelin, Leuprolide acetate, flutamide, bicalutamide, B 1089, CB 1093, KH 1060, vertoporfin (BPD-MA), Phthalocyanine, photosensitizer Pc4, demethoxyhypocrellin A (2BA-2-DMHA), interferon- α , interferon- γ , tumor-necrosis factor, Lovastatin, 1-methyl-4-phenylpyridinium ion, staurosporine, Actinomycin D, Dactinomycin, bleomycin A2, Bleomycin B2, Peplomycin, daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, Mitoxantrone, verapamil or thapsigargin.

25. The method of claim 22 wherein the cancer is of the colon, rectum,
25 prostate, liver, lung, bronchus, pancreas, brain, head, neck, stomach, skin, kidney, cervix, blood, larynx, esophagus, mouth, pharynx, testes, urinary bladder, ovary or uterus.

26. A method for treating stroke, epilepsy, Alzheimer's disease, or Parkinson's disease comprising administering to a patient in need thereof an effective amount of a compound having the structure:



35

or a pharmaceutically acceptable salt thereof,

wherein:

R₁ is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R₇;

5 R₂ and R₃ are the same or different and are independently hydrogen or lower alkyl;

R₄ represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;

10 R₅ and R₆ are the same or different and independently -R₈, -(CH₂)_aC(=O)R₉, -(CH₂)_aC(=O)OR₉, -(CH₂)_aC(=O)NR₉(CH₂)_bC(=O)R₁₀, -(CH₂)_aNR₉C(=O)R₁₀, -(CH₂)_aNR₁₁C(=O)NR₉R₁₀, -(CH₂)_aNR₉R₁₀, -(CH₂)_aOR₉, -(CH₂)_aSO_cR₉, or -(CH₂)_aSO₂NR₉R₁₀;

15 or R₅ and R₆ taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R₇ is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted 20 aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, -C(=O)OR₈, -OC(=O)R₈, -C(=O)NR₈R₉, -C(=O)NR₈OR₉, -SO_cR₈, -SO_cNR₈R₉, -NR₈SO_cR₉, -NR₈R₉, -NR₈C(=O)R₉, -NR₈C(=O)(CH₂)_bOR₉, -NR₈C(=O)(CH₂)_bR₉, -O(CH₂)_bNR₈R₉, or heterocycle fused to phenyl;

25 R₈, R₉, R₁₀ and R₁₁ are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;

or R₈ and R₉ taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;

30 a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/046170 A2

(51) International Patent Classification: Not classified

(21) International Application Number: PCT/US01/46402

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/251,904 6 December 2000 (06.12.2000) US

(71) Applicant: SIGNAL PHARMACEUTICALS, INC.
[US/US]; 5555 Oberlin Drive, San Diego, CA 92121 (US).

(72) Inventors: KOIS, Adam; 11363 Redbud Court, San Diego, CA 92127 (US). MACFARLANE, Karen, J.; 11435 Belshire Lane, San Diego, CA 92126 (US). SATOH, Yoshitaka; 11460 Larmier Circle, San Diego, CA 92131 (US). BHAGWAT, Shripad, S.; 5015 Ashley Falls Court, San Diego, CA 92130 (US). PARNE, Jason, S.; 12511 El Camino Real #C, San Diego, CA 92130 (US). PALANKI, Moorthy, S., S.; 602 Crest Drive, Encinitas, CA 92024 (US). ERDMAN, Paul, E.; 8225 Jade Coast #93, San Diego, CA 92126 (US).

(74) Agents: INSOGNA, Anthony, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with declaration under Article 17(2)(a); without classification and without abstract; title not checked by the International Searching Authority

(48) Date of publication of this revised version:

3 January 2003

(15) Information about Correction:

see PCT Gazette No. 01/2003 of 3 January 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/046170 A2

(54) Title: ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO

(57) Abstract:

PATENT COOPERATION TREATY

PCT

DECLARATION OF NON-ESTABLISHMENT OF INTERNATIONAL SEARCH REPORT

(PCT Article 17(2)(a), Rules 13ter.1(c) and Rule 39)

Applicant's or agent's file reference 10624-050-22	IMPORTANT DECLARATION	Date of mailing(day/month/year) 06/06/2002
International application No. PCT/US 01/ 46402	International filing date(day/month/year) 05/12/2001	(Earliest) Priority date(day/month/year) 06/12/2000
International Patent Classification (IPC) or both national classification and IPC		
Applicant SIGNAL PHARMACEUTICALS, INC.		

This International Searching Authority hereby declares, according to Article 17(2)(a), that no international search report will be established on the international application for the reasons indicated below

1. The subject matter of the international application relates to:
 - a. scientific theories.
 - b. mathematical theories
 - c. plant varieties.
 - d. animal varieties.
 - e. essentially biological processes for the production of plants and animals, other than microbiological processes and the products of such processes.
 - f. schemes, rules or methods of doing business.
 - g. schemes, rules or methods of performing purely mental acts.
 - h. schemes, rules or methods of playing games.
 - i. methods for treatment of the human body by surgery or therapy.
 - j. methods for treatment of the animal body by surgery or therapy.
 - k. diagnostic methods practised on the human or animal body.
 - l. mere presentations of information.
 - m. computer programs for which this International Searching Authority is not equipped to search prior art.
2. The failure of the following parts of the international application to comply with prescribed requirements prevents a meaningful search from being carried out:

the description the claims the drawings
3. The failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions prevents a meaningful search from being carried out:
 - the written form has not been furnished or does not comply with the standard.
 - the computer readable form has not been furnished or does not comply with the standard.
4. Further comments:

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Véronique Baillou
---	--

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 203

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

THIS PAGE BLANK (USPTO)